var title_f24_15_24816="Inspissated stool";
var content_f24_15_24816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain abdominal radiograph showing inspissated stool which might be mistaken for drug packets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stool predominantly in upper left quadrant of radiograph. Body packing was not suspected. Pellets of stool lack the geometric appearance of drug packets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Traub, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24816=[""].join("\n");
var outline_f24_15_24816=null;
var title_f24_15_24817="Alopecia areata";
var content_f24_15_24817=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Alopecia areata (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24817/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24817/contributors\" id=\"au840\">",
"       Andrew G Messenger, MD, FRCP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24817/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24817/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24817/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24817/contributors\" id=\"de2840\">",
"       Abena O Ofori, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/15/24817?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ALOPECIA AREATA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Alopecia areata is a skin condition that causes a sudden loss of patches of hair on the scalp and sometimes other parts of the body. It is nonscarring, which means that there is no permanent damage to the hair follicle. In most people, new hair eventually grows back in the affected areas, although this process can take months. Approximately 50 percent of people with mild alopecia areata recover within a year; however, most people will experience more than one episode during their lifetime.",
"    </p>",
"    <p>",
"     About one person in 50 will suffer from alopecia areata at some point in their life. It occurs in men and women of all races equally. The condition can develop at any age, although most people develop alopecia areata for the first time before the age of 30.",
"    </p>",
"    <p>",
"     Alopecia areata is not life threatening, and does not cause physical pain. However, the cosmetic effects of hair loss can be devastating.",
"    </p>",
"    <p>",
"     More detailed information about alopecia areata can be found separately (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"      \"Clinical manifestations and diagnosis of alopecia areata\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=see_link\">",
"      \"Management of alopecia areata\"",
"     </a>",
"     ). Androgenetic alopecia (male-pattern hair loss) is also discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"      \"Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ALOPECIA AREATA CAUSES AND RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     In alopecia areata, the body's immune system mistakenly attacks the hair follicles for reasons that are not clear. Fortunately, the follicles retain their ability to regrow hair, and the hair loss is not permanent in most cases.",
"    </p>",
"    <p>",
"     Other conditions can occur along with alopecia areata; these include vitiligo (a disorder that causes patchy whitening of the skin), thyroiditis (inflammation of the thyroid gland), and pernicious anemia (a decrease in the number of red blood cells due to a vitamin B12 deficiency). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link\">",
"      \"Vitiligo\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Approximately 20 percent of people with alopecia areata have a family member who is also affected. Based on this, experts believe that some people have a genetic predisposition to the disease [",
"     <a class=\"abstract\" href=\"UTD.htm?24/15/24817/abstract/1\">",
"      1",
"     </a>",
"     ]. A person who has a close relative with alopecia areata has a slightly increased risk of developing it as well. If the relative experienced hair loss before the age of 30, the risk is increased further.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ALOPECIA AREATA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     People with alopecia areata typically have smooth, round patches of complete hair loss that develop over a period of a few weeks, followed in most cases by regrowth over several months. However, alopecia areata may persist for several years and sometimes hair never regrows.",
"    </p>",
"    <p>",
"     The patches may enlarge and form bizarre patterns (",
"     <a class=\"graphic graphic_picture graphicRef50613 \" href=\"UTD.htm?33/60/34760\">",
"      picture 1",
"     </a>",
"     ). Short hairs, broken off a few millimeters from the scalp, are often found at the edges of expanding patches of hair loss. These are sometimes referred to as \"exclamation point hairs.\"",
"    </p>",
"    <p>",
"     The scalp is the most common site for hair loss, but any area of the body can be affected. For many people, the disease does not progress beyond patchy hair loss. However, in some cases the hair loss is extensive. A small minority of patients lose all the hair on their head (known as alopecia totalis) or all the hair on their head and body (alopecia universalis).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ALOPECIA AREATA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of alopecia areata is based upon the appearance of the hair loss. A healthcare provider will look for the characteristic patterns of hair loss, such as smooth patches with short, broken-off hairs around the borders.",
"    </p>",
"    <p>",
"     Biopsy (the removal of a sample of tissue for study) is usually not necessary. Blood tests for thyroid disease or pernicious anemia may be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PSYCHOSOCIAL IMPACT OF ALOPECIA AREATA",
"     </span>",
"    </p>",
"    <p>",
"     Losing one's hair can be a devastating experience, particularly because it develops suddenly and the loss is difficult to hide. Patients who have difficulty with the psychosocial impact of losing their hair should speak to a healthcare provider about their feelings. Providers can offer support and may recommend that a patient work with a therapist, clinical psychologist, or support group; individual and group therapy can help patients adjust and cope with hair loss, and may also provide tips on cosmetic coverings.",
"    </p>",
"    <p>",
"     In the United States, patients can contact the National Alopecia Areata Foundation (",
"     <a class=\"external\" href=\"file://www.alopeciaareata.org/\">",
"      www.alopeciaareata.org",
"     </a>",
"     ), a national support group that publishes a newsletter and provides names of local support groups.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      ALOPECIA AREATA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Not all people with alopecia areata require treatment; many patients with limited disease will experience spontaneous hair regrowth.",
"    </p>",
"    <p>",
"     For patients who use treatments, there are several options. However, alopecia areata cannot be \"cured\". As noted above, most patients experience future episodes of hair loss.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Corticosteroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Corticosteroids, commonly called steroids, are antiinflammatory medications that are used to treat alopecia areata. They can be taken by injection, applied topically (as a cream or lotion), or taken by mouth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Injected corticosteroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;This method of treatment is often recommended for adults with isolated patches of hair loss. The medication is injected directly into the affected area to stimulate hair regrowth (",
"     <a class=\"graphic graphic_picture graphicRef68653 \" href=\"UTD.htm?22/42/23205\">",
"      picture 2",
"     </a>",
"     ). New growth is usually seen within four weeks; injections are repeated every four to six weeks until regrowth is complete.",
"    </p>",
"    <p>",
"     Because injections can be painful, the affected area may be pretreated with a topical anesthetic cream. The cream should be applied generously and covered with a tightly fitting shower cap or plastic wrap for 1.5 to 2 hours before treatment. The cream is removed immediately before injection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Topical corticosteroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although topical corticosteroids (ointments, lotions, gels, creams, or foam) are often used, there is limited evidence to support their effectiveness. They may work best when used in combination with other topical treatments, such as minoxidil (see below), or injected corticosteroids [",
"     <a class=\"abstract\" href=\"UTD.htm?24/15/24817/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Topical minoxidil",
"     </span>",
"     &nbsp;&mdash;&nbsp;Available over-the-counter, topical minoxidil (eg, Rogaine&reg;) promotes hair growth by lengthening the growth phase of hair follicles and causing more follicles to produce hair [",
"     <a class=\"abstract\" href=\"UTD.htm?24/15/24817/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Minoxidil is approved to treat androgenetic alopecia (male pattern hair loss); it may also be useful in patients with mild alopecia areata. The solution is typically applied twice a day to the area of hair loss, and can be used alone or in combination with other therapies. When treatment is successful, new hair growth is seen in about 12 weeks. Minoxidil is not effective in patients with severe alopecia areata or total loss of scalp hair.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Anthralin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anthralin is a treatment that was originally developed for the treatment of another skin condition, psoriasis, but was later found to regrow hair in some people with mild alopecia. It must be used with care because it irritates the skin and eyes and can stain fabrics. Hair regrowth may be seen within three to four months.",
"    </p>",
"    <p>",
"     Given that treatment with anthralin is uncomfortable and of limited benefit, we generally do not recommend it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Topical immunotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Topical immunotherapy is probably the most effective treatment for patients with extensive or recurrent scalp involvement. This technique involves applying a substance known to cause an allergic reaction to the area of hair loss. The resulting itching, scaling, and irritation often induce hair growth for reasons that are not completely understood.",
"    </p>",
"    <p>",
"     Topical immunotherapy is not widely available in the United States. Patients who are interested in trying it should see a dermatologist (physician specializing in the skin) who is experienced with this treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Photochemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In photochemotherapy, the person is given a light-sensitive drug (either applied to the skin or taken by mouth) and then exposed to an ultraviolet light source. Studies have shown conflicting results. However, a trial of photochemotherapy may be reasonable in people with extensive alopecia areata if topical immunotherapy is not available. Treatment is usually continued for four to six months.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      COSMETIC APPROACHES TO ALOPECIA AREATA",
"     </span>",
"    </p>",
"    <p>",
"     Female patients with extensive alopecia areata usually opt to purchase a wig or hairpiece. An attractive wig is important for many women and children, although high-quality wigs can be expensive. Wigs can be cut and styled according to an individual's preference and may be attached to the head with double-sided tape or a suction cap.",
"    </p>",
"    <p>",
"     Men frequently opt to shave their scalp; wigs and hairpieces are generally less acceptable. Temporary tattooing can be helpful for the loss of eyebrows. False eyelashes are an option for patients with hair loss involving the eyelashes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498521237\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676531\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/18/7458?source=see_link\">",
"      Patient information: Hair loss in men and women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12676549\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/56/17282?source=see_link\">",
"      Patient information: Hair loss in men and women (androgenetic alopecia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4330?source=see_link\">",
"      Management of alopecia areata",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link\">",
"      Vitiligo",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Alopecia Areata Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.naaf.org/\">",
"      www.naaf.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Hair Loss Council",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ahlc.org/\">",
"      www.ahlc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Dermatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aad.org/\">",
"      www.aad.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     UpToDate wishes to acknowledge Kelly Crowley for her contributions to this topic.",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/15/24817/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/15/24817?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24817/abstract/1\">",
"      Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24817/abstract/2\">",
"      Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006; 20:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24817/abstract/3\">",
"      Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987; 16:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24817/abstract/4\">",
"      Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24817/abstract/5\">",
"      Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol 2012; 166:916.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_15_24817=[""].join("\n");
var outline_f24_15_24817=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ALOPECIA AREATA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ALOPECIA AREATA CAUSES AND RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ALOPECIA AREATA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ALOPECIA AREATA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PSYCHOSOCIAL IMPACT OF ALOPECIA AREATA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           ALOPECIA AREATA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           COSMETIC APPROACHES TO ALOPECIA AREATA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/60/34760\" title=\"picture 1\">",
"           Alopecia areata PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/42/23205\" title=\"picture 2\">",
"           Steroid injection PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24818="Nonallergic rhinitis (runny or stuffy nose)";
var content_f24_15_24818=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Nonallergic rhinitis (runny or stuffy nose) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24818/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24818/contributors\" id=\"au323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24818/contributors\" id=\"au6339\">",
"       Phillip L Lieberman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24818/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24818/contributors\" id=\"se952\">",
"       Jonathan Corren, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/15/24818/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24818/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/15/24818?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      NONALLERGIC RHINITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Rhinitis refers to inflammation of the nasal passages. This inflammation can cause a variety of annoying symptoms, including sneezing, itching, nasal congestion, runny nose, and postnasal drip (the sensation that mucus is draining from the sinuses down the back of the throat).",
"    </p>",
"    <p>",
"     Almost everyone experiences rhinitis at some point during their life. Brief episodes of rhinitis are usually caused by respiratory tract infections with viruses (eg, the common cold). Chronic rhinitis is usually caused by allergies, but it can also occur from overuse of certain drugs, some medical conditions, and other unidentifiable factors.",
"    </p>",
"    <p>",
"     This topic discusses nonallergic rhinitis. A separate topic discusses rhinitis caused by allergies. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"      \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS NONALLERGIC RHINITIS?",
"     </span>",
"    </p>",
"    <p>",
"     Nonallergic rhinitis is the medical term used to describe the following symptoms when they occur without a known allergic cause:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sneezing",
"      </li>",
"      <li>",
"       Runny nose",
"      </li>",
"      <li>",
"       Stuffy nose (congestion)",
"      </li>",
"      <li>",
"       Postnasal drip",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Symptoms are usually present year-round, although they may be worsened by certain weather conditions (eg, those that accompany changes of season). The condition does not usually develop until adulthood.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      NONALLERGIC RHINITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause of nonallergic rhinitis is not usually known. However, many triggers of symptoms are known, and include tobacco smoke, traffic fumes, or strong odors and perfumes. People with nonallergic rhinitis are not bothered by pollen or furred animals (the common triggers in allergic rhinitis), although about one-half of people with this condition also have allergic rhinitis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"      \"Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      NONALLERGIC RHINITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of nonallergic rhinitis includes trigger avoidance, medications,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     nasal rinsing or irrigation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Trigger avoidance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exposure to tobacco smoke can be reduced if household members stop smoking or smoke only outside of the home. It is also important to avoid smoke exposure in the workplace.",
"    </p>",
"    <p>",
"     Exposure to pollutants and irritants can be reduced by avoiding wood-burning stoves and fireplaces; properly venting other stoves and heaters; and avoiding cleaning agents and household sprays that trigger symptoms.",
"    </p>",
"    <p>",
"     Exposure to strong perfumes and scented products may be more difficult. People who are bothered by these items should avoid using them and may need to request that coworkers, family, or friends do the same. Some workplaces have policies regarding the use of strongly scented personal products.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Nasal rinsing and irrigation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Simply rinsing the nose with a salt water (saline) solution one or more times a day is helpful for many patients with nonallergic rhinitis, as well as for other rhinitis conditions. Nasal rinsing is particularly useful for symptoms of postnasal drainage. Nasal rinsing can be done before use of nasal medication, so that the lining is freshly cleansed when the medication is applied.",
"    </p>",
"    <p>",
"     The nose can be rinsed with small amounts of saline by using over-the-counter saline nasal sprays, or with larger amounts of saline. The latter technique is called nasal irrigation or nasal lavage. Nasal sprays are easy to use, but do not rinse the nasal passages as thoroughly as nasal irrigation. However, nasal irrigation is less convenient and takes more time.",
"    </p>",
"    <p>",
"     A variety of devices, including bulb syringes, irrigation pots (which look like small kettles), and bottle sprayers, may be used to perform nasal irrigation; instructions for the technique are provided in the table (",
"     <a class=\"graphic graphic_table graphicRef71059 \" href=\"UTD.htm?42/33/43548\">",
"      table 1",
"     </a>",
"     ). At least 200 mL (about three-quarters cup) of fluid is recommended for each nostril. Patients can make their own solution or buy commercially-prepared solutions. All are available without a prescription.",
"    </p>",
"    <p>",
"     Nasal irrigation with warmed saline can be performed as needed, once per day, or twice daily for increased symptoms. Nasal irrigation carries few risks when performed correctly. Very rare brain infections have been reported from the use of water that was contaminated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Medications that worsen symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain medications can cause or worsen nasal symptoms (especially congestion). These include the following: birth control pills, some drugs for high blood pressure (eg, alpha blockers and beta blockers), antidepressants, medications for erectile dysfunction, and some medications for prostatic enlargement. If rhinitis symptoms are bothersome and one of these medications is used, ask the prescriber if the medication could be aggravating the condition.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Medications that may help symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Daily use of a nasal glucocorticoid (steroid)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     an antihistamine nasal spray can be helpful for people with nonallergic rhinitis. These medications may be used alone or in combination.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Nasal antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;A prescription nasal antihistamine spray, such as azelastine (eg, Astelin, Astepro), can relieve symptoms of postnasal drip, congestion, and sneezing. These sprays start to work within minutes after use and can be used to treat symptoms after they develop. However, they are most effective when used on a regular basis.",
"    </p>",
"    <p>",
"     The most common side effect of nasal antihistamines is a bad taste in the mouth immediately after use. This can be minimized by keeping the head tilted forward while spraying, to prevent the medicine from draining down the throat. The usual dose of azelastine is two sprays in each nostril twice per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Nasal glucocorticoids (steroids)",
"     </span>",
"     &nbsp;&mdash;&nbsp;A nasal glucocorticoid (steroid), fluticasone (eg, Flonase, generic equivalents), has been shown to be effective for symptoms of nonallergic rhinitis. The dose is one squirt in each nostril twice per day. Other glucocorticoid (steroid) nasal sprays may also be effective, although these have not been directly studied in people with nonallergic rhinitis.",
"    </p>",
"    <p>",
"     Some symptom relief may occur on the first day of treatment, although the maximal effect may not be noticeable for days to weeks. For this reason, fluticasone is most effective when used regularly. Some people are able to use lower doses when symptoms are less severe. (See",
"     <a class=\"local\" href=\"#H12\">",
"      'How to use a nasal spray'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Nasal ipratropium",
"     </span>",
"     &nbsp;&mdash;&nbsp;A runny nose with profuse, watery discharge from the nose (rhinorrhea) can be treated with ipratropium bromide (0.03 percent or 0.6 percent) nasal spray. Ipratropium is the best treatment for gustatory rhinitis. (See",
"     <a class=\"local\" href=\"#H16\">",
"      'Gustatory rhinitis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1283833\">",
"     <span class=\"h3\">",
"      Combination nasal antihistamine and nasal glucocorticoid (steroid)",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is a nasal spray (Dymista) that contains both azelastine and fluticasone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      How to use a nasal spray",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal sprays work best when they are used properly and the medication remains in the nose, rather than draining down the back of the throat. Some people find that holding one nostril closed with a finger improves their ability to draw the spray into the upper nose. Medicine that drains into the throat should be spit out, since the medicine is only effective when it remains in the nose.",
"    </p>",
"    <p>",
"     The head should be positioned normally or with the chin slightly tucked. The spray should be directed away from the nasal septum (the cartilage that divides the two sides of the nose). The spray is dispensed and then sniffed in slightly to pull it into the higher parts of the nose. Sniffing too hard will result in the medicine draining down the throat, and should be avoided.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Decongestants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Oral decongestant medications (like pseudoephedrine or phenylephrine) help to relieve symptoms of congestion (stuffiness) in some people. However, this treatment is not usually recommended unless nasal antihistamines and nasal glucocorticoids (steroids) do not improve symptoms.",
"    </p>",
"    <p>",
"     Several decongestant nasal sprays also are available, including oxymetazoline (Afrin) and phenylephrine (Neo-synephrine). Nasal decongestants should not be used for more than two to three days at a time because they may cause a type of rhinitis called rhinitis medicamentosa. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Rhinitis medicamentosa'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Oral decongestants elevate blood pressure and may not be appropriate for people with high blood pressure or certain cardiovascular conditions. In addition, oral decongestants can cause nervousness and difficulty sleeping. Men with an enlarged prostate who have difficulty urinating may notice a worsening of this problem when they take decongestants. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"      \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      How long will I need treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The dose or frequency of medications can be reduced in some patients over time. However, in most patients, symptoms are lifelong and some medication is usually needed on a daily and long-term basis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      OTHER TYPES OF NONALLERGIC RHINITIS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Gustatory rhinitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gustatory rhinitis is the term used to describe the sudden onset of watery nasal discharge with eating, especially foods that are spicy or heated (such as soup).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Rhinitis medicamentosa",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rhinitis medicamentosa is a type of rhinitis that develops as a result of overuse of over-the-counter decongestant nasal sprays or from snorting cocaine (this does",
"     <strong>",
"      not",
"     </strong>",
"     happen with use of nasal glucocorticoid [steroid] sprays). Oral medications can also cause rhinitis medicamentosa. (See",
"     <a class=\"local\" href=\"#H7\">",
"      'Medications that worsen symptoms'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Rhinitis medicamentosa is treated by discontinuing the drug that is causing the condition. Steroid nasal sprays can speed the recovery from this condition.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H863373188\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517117\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5517125\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/8/41092?source=see_link\">",
"      Patient information: Allergic rhinitis (seasonal allergies) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H863373194\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"      An overview of rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18519?source=see_link\">",
"      Atrophic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12250?source=see_link\">",
"      Chronic nonallergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link\">",
"      Occupational rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6775?source=see_link\">",
"      Pathogenesis of allergic rhinitis (rhinosinusitis)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Otolaryngology (Head and Neck Surgery)",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.entnet.org/\">",
"        www.entnet.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Allergy, Asthma, &amp; Immunology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.aaaai.org/patients/publicedmat/tips/rhinitis.stm\">",
"        www.aaaai.org/patients/publicedmat/tips/rhinitis.stm",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Rhinologic Society",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.american-rhinologic.org/\">",
"        www.american-rhinologic.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/15/24818/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/15/24818?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24818/abstract/1\">",
"      Carr WE, Van Bavel J, Lieberman P, et al. MP29-02 provides rapid and more complete nasal symptom relief than two first-line therapies: A retrospective analysis of a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2013; 131:AB114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24818/abstract/2\">",
"      Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24818/abstract/3\">",
"      van Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy 2005; 60:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24818/abstract/4\">",
"      Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol 2001; 86:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24818/abstract/5\">",
"      Berger WE, Schonfeld JE. Nonallergic rhinitis in children. Curr Allergy Asthma Rep 2007; 7:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_15_24818=[""].join("\n");
var outline_f24_15_24818=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           NONALLERGIC RHINITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS NONALLERGIC RHINITIS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           NONALLERGIC RHINITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           NONALLERGIC RHINITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           OTHER TYPES OF NONALLERGIC RHINITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43548\" title=\"table 1\">",
"           Nasal irrigation instruct",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24819="Pulm AVM PA gram V";
var content_f24_15_24819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulmonary venous phase shows abnormally dilated distorted pulmonary veins, but no right-to-left shunt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24819=[""].join("\n");
var outline_f24_15_24819=null;
var title_f24_15_24820="Calcium citrate: Patient drug information";
var content_f24_15_24820=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium citrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     see \"Calcium citrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=see_link\">",
"     see \"Calcium citrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cal-C-Caps [OTC];",
"     </li>",
"     <li>",
"      Cal-Cee [OTC];",
"     </li>",
"     <li>",
"      Cal-Citrate&trade; 225 [OTC];",
"     </li>",
"     <li>",
"      Calcitrate [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osteocit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off or treat soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691428",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low calcium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, kidney stones, or low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron, zinc, or folic acid within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after a high bran or fiber meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 to 3 hours after meals as an antacid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Soft, brittle bones (osteoporosis):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11305 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24820=[""].join("\n");
var outline_f24_15_24820=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855607\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014205\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014204\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014209\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014210\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014212\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014207\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014208\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014213\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014214\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=related_link\">",
"      Calcium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/2/29733?source=related_link\">",
"      Calcium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24821="Central line SC supra anat";
var content_f24_15_24821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External landmarks for the supraclavicular approach to the subclavian vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24821=[""].join("\n");
var outline_f24_15_24821=null;
var title_f24_15_24822="Interferon alfacon-1 (consensus interferon): Drug information";
var content_f24_15_24822=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon alfacon-1 (consensus interferon): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/16/6406?source=see_link\">",
"    see \"Interferon alfacon-1 (consensus interferon): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Infergen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic HCV infection:",
"     </b>",
"     SubQ: 9 mcg 3 times/week for 24 weeks; allow 48 hours between doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Combination therapy with ribavirin:",
"     </i>",
"     SubQ: 15 mcg/day with ribavirin for up to 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Patients who have previously tolerated interferon therapy but did not respond or relapsed:",
"     </i>",
"     15 mcg 3 times/week week for up to 48 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not indicated for patients &lt;18 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10934782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Hepatitis C: Avoid combination therapy with ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F183394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in decompensated hepatic disease (Child-Pugh class B or C) is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F183411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dose should be held in patients who experience a severe adverse reaction, and treatment should be stopped or decreased if the reaction does not become tolerable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Doses were reduced from 9 mcg to 7.5 mcg in the pivotal study.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For patients receiving 15 mcg/dose, doses were reduced in 3 mcg decrements. Efficacy is decreased with doses &lt;7.5 mcg.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infergen&reg;: 30 mcg/mL (0.3 mL, 0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7882090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088613.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088613.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferon alfacon-1 is administered by SubQ injection, 3 times/week, with at least 48 hours between doses. Allow to reach room temperature just prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic hepatitis C virus (HCV) infection in patients &ge;18 years of age with compensated liver disease and anti-HCV serum antibodies or HCV RNA; concurrent use with ribavirin in HCV-infected patients who have failed treatment with pegylated interferon/ribavirin (Bacon, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5102883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Interferon alfacon-1 may be confused with interferon alfa-2a, interferon alfa-2b, interferon alfa-n3, peginterferon alfa-2b",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Interferon alfacon-1 may be confused with interferon alpha multi-subtype which is available in international markets",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported using 9 mcg/dose interferon alfacon-1 3 times/week. Flu-like symptoms (which included headache, fatigue, fever, myalgia, rigors, arthralgia, and increased diaphoresis) were the most commonly reported adverse reaction; this was reported separately from flu-like syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (82%), fatigue (69%), fever (61%), insomnia (39%), nervousness (31%), depression (26%), dizziness (22%), anxiety (19%), emotional lability (12%), malaise (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (14%), pruritus (14%), rash (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (41%), nausea (40%), diarrhea (29%), anorexia (24%), dyspepsia (21%), vomiting (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Granulocytopenia (23%), thrombocytopenia (3% to 19%), leukopenia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site erythema (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (58%), rigors (57%), body pain (54%), arthralgia (51%), back pain (42%), limb pain (26%), neck pain (14%), skeletal pain (14%), paresthesia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (34%), upper respiratory tract infection (31%), cough (22%), sinusitis (17%), rhinitis (13%), respiratory tract congestion (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (15%), diaphoresis increased (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (9%), hypertension (5%), tachycardia (4%), palpitation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Amnesia (10%), hypoesthesia (10%), abnormal thinking (8%), agitation (6%), confusion (4%), somnolence (4%), apathy (2%), hyperesthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (6%), erythema (6%), dry skin (6%), wound (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid test abnormalities (9%), dysmenorrhea (9%), triglycerides increased (6%), menstrual disorder (6%), decreased libido (5%), hypothyroidism (4%), menorrhagia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (9%), flatulence (8%), toothache (7%), salivation decreased (6%), hemorrhoids (6%), weight loss (5%), taste perversion (3%), stomatitis (3%), gingivitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (8%), genital moniliasis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased (5%), hemoglobin decreased (4%), anemia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver tenderness (5%), hepatomegaly (3%), prothrombin time increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (9%), access pain (8%), injection site bruising (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (9%), hypertonia (7%), musculoskeletal disorder (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (8%), eye pain (5%), vision abnormalities (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (6%), earache (5%), otitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract congestion (10%), epistaxis (8%), dyspnea (7%), bronchitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (7%), lymphadenopathy (6%), lymphocytosis (5%), infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (limited to important or life-threatening): Abdominal distension, abnormal gait, arthritis, ascites, ataxia, autoimmune disorders exacerbated, bone pain, cerebrovascular hemorrhage, cerebrovascular ischemia, creatinine increased, dehydration, delusion, diabetes, gastritis, gastrointestinal bleeding, hallucinations, hearing impairment, hearing loss, hemorrhage, hemorrhagic/ischemic colitis, hepatic encephalopathy, hepatic function abnormal, hyperbilirubinemia, hyperglycemia, hypersensitivity, injection site necrosis, injection site ulcer, jaundice, loss of consciousness, memory impairment, pancreatitis, pyoderma gangrenosum, renal failure, rhabdomyolysis, seizure, sepsis, speech disorder, tachyarrhythmias, toxic epidermal necrolysis, transaminases increased, tremor, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to interferon alfacon-1 or any component of the formulation, other alpha interferons, or",
"     <i>",
"      E. coli",
"     </i>",
"     -derived products; decompensated liver disease (Child-Pugh class B and C); autoimmune hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; discontinue for ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Use with caution in patients with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. May worsen when used in combination with ribavirin; use caution in patients with ANC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: Hypotension, palpitations, tachycardia, and tachyarrhythmias have been reported with interferon alfacon-1use. Alfa interferon treatment has been associated with supraventricular arrhythmias, chest pain and MI. Use with caution in patients with pre-existing cardiac disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis have been observed with interferon alfa treatment, including alfacon-1; may be severe and/or life-threatening; discontinue if symptoms (eg, abdominal pain, bloody diarrhea, and/or fever) develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Acute hypersensitivity reactions have been reported (rarely) with alfa interferons.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxicity: Increases in serum creatinine and (rarely) renal failure have been reported with use; monitor closely for signs/symptoms of toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe psychiatric adverse events (eg, depression, psychosis, mania, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms;",
"     </b>",
"     use with extreme caution in patients with a history of depression. Careful neuropsychiatric monitoring is required during therapy. Patients developing severe depression may require discontinuation of treatment. Although dose reduction or discontinuation may resolve symptoms, depression may persist; suicides have been reported after therapy with alfa interferons has been discontinued. Use with caution in patients with seizure disorders, brain metastases, or compromised CNS function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Decreased/loss of vision, retinopathy (including macular edema), retinal artery or vein thrombosis, retinal hemorrhages, cotton wool spots, optic neuritis, papilledema, and retinal detachment have occurred in patients receiving other alpha interferons. Use caution in patients with pre-existing ophthalmic disorders; monitor closely and discontinue with new or worsening ophthalmic symptoms. Visual exams are recommended for patients with diabetes mellitus or hypertensive retinopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Has been observed (occasionally fatal); hypertriglyceridemia increases the risk for pancreatitis; discontinue treatment in patients with confirmed pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: May occur in combination with telbivudine; interrupt treatment for suspected peripheral neuropathy and discontinue if confirmed; symptoms may be reversible with discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonia, pulmonary hypertension, and sarcoidosis, resulting in potential fatal respiratory failure may occur with interferon alfa treatment, including interferon alfacon-1. Discontinue with unexplained pulmonary infiltrates or evidence of impaired pulmonary function. Use caution in patients with a history of pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid use in patients with history of autoimmune disorders.",
"     </b>",
"     Development or exacerbation of autoimmune disorders (thrombocytopenic purpura, vasculitis, Raynaud&rsquo;s disease, rheumatoid arthritis, interstitial nephritis, thyroiditis, lupus erythematosus, and rhabdomyolysis) has been associated with interferon alfa. Monitor closely and consider discontinuing if autoimmune disease develops. Use is contraindicated in patients with autoimmune hepatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; hyperglycemia has been reported which may require adjustments in medications. Discontinue interferon alfacon-1 if unable to control blood sugars with medication during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at risk for hepatic decompensation with alfa interferon therapy. Monitor closely; discontinue with signs (eg, jaundice, ascites, coagulopathy, hypoalbuminemia) of hepatic decompensation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis C (chronic): Not for use as monotherapy; concurrent use with ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate fatal or life-threatening infectious disorders;",
"     </b>",
"     discontinue treatment for persistent severe or worsening symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate fatal or life-threatening ischemic disorders;",
"     </b>",
"     discontinue treatment for persistent severe or worsening symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; interferon alfacon-1 has not been studied in these patients. Monitor closely. Combination therapy with ribavirin (hepatitis C) should not be used in patients with reduced renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Use with caution in patients with pre-existing thyroid disease; thyroid disorders (hyper- or hypothyroidism) have been reported. Discontinue interferon alfacon-1 if unable to control thyroid disorders with medication during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination therapy with ribavirin:",
"     <b>",
"      [U.S. Boxed Warning]: Combination treatment with ribavirin may cause birth defects and/or fetal mortality; hemolytic anemia (which may worsen cardiac disease), and may possibly be carcinogenic.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Use with caution in chronically-immunosuppressed patients, including transplantation recipients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferons without the concurrence of their healthcare provider.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There have been no well-controlled studies in pregnant women. Animal studies have shown embryolethal or abortifacient effects. Males and females who are being treated with interferon alfacon-1 should use effective contraception.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Women with hepatitis C should be instructed that there is a theoretical risk the virus may be transmitted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F183379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Infergen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mcg/0.3 ml (0.3 mL): $173.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mcg/0.5 mL (0.5 mL): $173.79",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemoglobin and hematocrit; white blood cell count; platelets; triglycerides; thyroid function. Laboratory tests should be taken prior to therapy, 2 weeks after therapy has begun, and periodically during treatment. HCV RNA, ALT to determine success/response to therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The following guidelines were used during the clinical studies as acceptable baseline values:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;100 g/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &ge;1500 x 10",
"     <sup>",
"      6",
"     </sup>",
"     /L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;180 micromole/L (&lt;2 mg/dL) or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;0.83 mL/second (&gt;50 mL/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum albumin &ge;25 g/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &le;1.4 mg/dL (except for patients with Gilbert&rsquo;s syndrome)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     WNL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients should also be monitored for signs of depression. Patients with pre-existing diabetes mellitus or hypertensive retinopathy should have a baseline ophthalmic exam and periodic exams during therapy.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Infergen (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PL, PT, RU, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferon alfacon-1 is a member of the alpha interferon family of proteins, which are produced by nucleated cells, and have antiviral, antiproliferative, and immune-regulating activity. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected. Interferons induce gene transcription, inhibit cellular growth, alter the state of cellular differentiation, interfere with oncogene expression, alter cell surface antigen expression, increase phagocytic activity of macrophages, and augment cytotoxicity of lymphocytes for target cells. Although all alpha interferons share similar properties, the actual biological effects vary between subtypes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacokinetic studies have not been conducted on patients with chronic hepatitis C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Time to peak: Healthy volunteers: 24-36 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24822/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bacon BR, Shiffman ML, Mendes F, et al, &ldquo;Retreating Chronic Hepatitis C With Daily Interferon Alfacon-1/Ribavirin After Nonresponse to Pegylated Interferon/Ribavirin: DIRECT Results,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(6):1838-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24822/abstract-text/19291790/pubmed\" id=\"19291790\" target=\"_blank\">",
"        19291790",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8756 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24822=[""].join("\n");
var outline_f24_15_24822=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708948\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183410\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183392\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183406\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183393\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10934782\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183394\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183411\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183372\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183357\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7882090\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183374\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183373\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5102883\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183408\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183377\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183361\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299521\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183365\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183367\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183380\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183398\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183381\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183379\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183369\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183382\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183360\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183376\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8756\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8756|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/16/6406?source=related_link\">",
"      Interferon alfacon-1 (consensus interferon): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24823="Methohexital: Drug information";
var content_f24_15_24823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methohexital: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/4/17476?source=see_link\">",
"    see \"Methohexital: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"    see \"Methohexital: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brevital&reg; Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevital&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Barbiturate;",
"     </li>",
"     <li>",
"      General Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia (doses must be titrated to effect):",
"     </b>",
"     I.V.: Induction: 1-1.5 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Procedural sedation (unlabeled dose):",
"     </b>",
"     I.V.: 0.75-1 mg/kg; can redose 0.5 mg/kg every 2-5 minutes as needed (Bahn, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Wada test (unlabeled use):",
"     </b>",
"     I.V.: 3-4 mg over 3 seconds; following signs of recovery, administer a second dose of 2 mg over 2 seconds (Buchtel, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=see_link\">",
"      see \"Methohexital: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     Doses must be titrated to effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;1 month: Safety and efficacy not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;1 month and Children: Induction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 6.6-10 mg/kg of a 5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal: Usual: 25 mg/kg of a 1% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. (unlabeled dose): 1-2 mg/kg/dose of a 1% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Procedural sedation (unlabeled dose):",
"     </b>",
"     Infants &ge;1 month and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 0.5 mg/kg; may repeat 0.5 mg/kg to a maximum total dose of 2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 25 mg/kg of a 10% (100 mg/mL) solution given 5-15 minutes prior to procedure; maximum dose 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Refer to adult dosing. Reduce dose or administer at the low end of the dosage range.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F194476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower dosage and monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevital&reg; Sodium: 500 mg, 2.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F194501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F194459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Dilute to a maximum concentration of 1% for I.V. use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Induction and maintenance of anesthesia: 1% (10 mg/mL) solution is administered I.V. at a rate of ~1 mL/5 seconds or ~2 mg/second",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Wada testing: Dilution of 0.1% (1 mg/mL) has been used; administer I.V. at a rate of 1 mg/second",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M. administration: Use 5% (50 mg/mL) solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal administration: Use 1% (10 mg/mL) solution; 10% (100 mg/mL) solution has also been used (Pomeranz, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F194505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Solutions are alkaline (pH 9.5-11) and",
"     <b>",
"      incompatible",
"     </b>",
"     with acids (eg, atropine sulfate, succinylcholine, silicone); also",
"     <b>",
"      incompatible",
"     </b>",
"     with phenol-containing solutions and silicone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Fenoldopam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Atropine, glycopyrrolate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of anesthesia; procedural sedation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F194496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wada test",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Brevital&reg; may be confused with Brevibloc&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiorespiratory arrest, circulatory depression, hypotension, peripheral vascular collapse, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, emergence delirium, headache, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, salivation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain, nerve injury adjacent to injection site, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Involuntary muscle movement, radial nerve palsy, rigidity, tremor, twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, bronchospasm, cough, dyspnea, hiccups, laryngospasm, respiratory depression, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barbiturates, methohexital, or any component of the formulation; porphyria (latent or manifest); patients in whom general anesthesia is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in hemodynamically unstable patients (hypotension or shock) or severe hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with severe anemia; respiratory depression may occur leading to further inadequate tissue oxygenation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including heart failure; consider monitoring cardiac function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may prolong or potentiate hypnotic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients with extreme obesity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary disease: May cause respiratory depression; use with caution in patients with pulmonary disease. Use with caution in patients with asthma and chronic obstructive pulmonary disease.  Use with extreme caution in patients with ongoing status asthmaticus; hiccups, coughing, laryngospasm, and muscle twitching have occurred impairing ventilation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; may prolong or potentiate hypnotic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; closely monitor elderly or debilitated patients for impaired cognitive or motor performance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Should only be administered in hospitals or ambulatory care settings with continuous monitoring of respiratory function; resuscitative drugs, age- and size-appropriate intubation equipment and trained personnel experienced in handling their use should be readily available. For deeply sedated patients, a healthcare provider other than the individual performing the procedure should be present to continuously monitor the patient.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cumulative effect: Repeated dosing or continuous infusions may cause cumulative effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravenous (I.V.) administration: Prior to I.V. administration, ensure patient has adequate I.V. access; extravasation or intra-arterial injection causes necrosis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6743972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not shown fetal or maternal harm. There are no adequate and well-controlled studies in pregnant women. Methohexital crosses the placenta. Use only if potential benefit outweighs risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6743974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6743975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methohexital is minimally excreted in breast milk and levels decline rapidly after administration. Interruption of breast-feeding is unnecessary.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Brevital Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 g (1): $236.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $55.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6744063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory status (for moderate sedation, includes pulse oximetry and capnography), cardiovascular status, CNS status (when used for procedures monitor sedation level); cardiac monitor and blood pressure monitor required",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Brevimytal Natrium (DE);",
"     </li>",
"     <li>",
"      Brevital (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Brietal (DK, FI, GB, HN, HU, NO, PL, SE, TW);",
"     </li>",
"     <li>",
"      Brietal sodique (FR, LU);",
"     </li>",
"     <li>",
"      Brietal Sodium (AT, BF, BJ, CH, CI, ET, GB, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, RU, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Brietal-Sodium (AU, CZ, HU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultra short-acting I.V. barbiturate anesthetic",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Immediate; I.M. (pediatrics): 2-10 minutes; Rectal (pediatrics): 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Single dose: I.V.: 10-20 minutes; Rectal: 45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:  Hepatic via demethylation and oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bahn EL and Holt KR, \"Procedural Sedation and Analgesia: A Review and New Concepts,\"",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2005, 23(2):503-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/15829394/pubmed\" id=\"15829394\" target=\"_blank\">",
"        15829394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bjorkman S, Gabrielsson J, Quaynor H, et al, &ldquo;Pharmacokinetics of I.V. and Rectal Methohexitone in Children,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1987, 59(12):1541-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/3426908/pubmed\" id=\"3426908\" target=\"_blank\">",
"        3426908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchtel HA, Passaro EA, Selwa LM, et al, &ldquo;Sodium Methohexital (Brevital) as an Anesthetic in the Wada Test,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2002, 43(9):1056-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/12199731/pubmed\" id=\"12199731\" target=\"_blank\">",
"        12199731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cot&eacute; CJ, &ldquo;Sedation for the Pediatric Patient,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(1):31-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/8295806/pubmed\" id=\"8295806\" target=\"_blank\">",
"        8295806",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Folkerts H, &ldquo;Spontaneous Seizure After Concurrent Use of Methohexital Anesthesia For Electroconvulsive Therapy and Paroxetine: A Case Report,&rdquo;",
"      <i>",
"       J Nerv Ment Dis",
"      </i>",
"      , 1995, 183(2):115-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/7844577/pubmed\" id=\"7844577\" target=\"_blank\">",
"        7844577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes RB, Murray DJ, Dillman JB, et al, &ldquo;Pharmacokinetics of Two Percent Rectal Methohexitone in Children,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 1989, 36(2):160-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/2650897/pubmed\" id=\"2650897\" target=\"_blank\">",
"        2650897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johns FR, Sandler NA, Buckley MJ, et al, &ldquo;Comparison of Propofol and Methohexital Continuous Infusion Techniques for Conscious Sedation,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 1998, 56(10):1124-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/9766535/pubmed\" id=\"9766535\" target=\"_blank\">",
"        9766535",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss B and Green SM, &ldquo;Procedural Sedation and Analgesia in Children,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9512):766-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/16517277/pubmed\" id=\"16517277\" target=\"_blank\">",
"        16517277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pomeranz ES, Chudnofsky CR, Deegan TJ, et al, &ldquo;Rectal Methohexital Sedation for Computed Tomography Imaging of Stable Pediatric Emergency Department Patients,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):1110-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/10790471/pubmed\" id=\"10790471\" target=\"_blank\">",
"        10790471",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sedik H, &ldquo;Use of Intravenous Methohexital as a Sedative in Pediatric Emergency Departments,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2001, 155(6):665-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/11386953/pubmed\" id=\"11386953\" target=\"_blank\">",
"        11386953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwanda AE, Freyer DR, Sanfilippo DJ, et al, &ldquo;Brief Unconscious Sedation for Painful Pediatric Oncology Procedures,&rdquo;",
"      <i>",
"       Am J Pediatr Hematol Oncol",
"      </i>",
"      , 1993, 15(4):370-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/8214358/pubmed\" id=\"8214358\" target=\"_blank\">",
"        8214358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Urquhart ML and White PF, &ldquo;Comparison of Sedative Infusions During Regional Anesthesia-Methohexital, Etomidate, and Midazolam,&rdquo;",
"      <i>",
"       Anest Analg",
"      </i>",
"      , 1989, 68(3):249-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/2919762/pubmed\" id=\"2919762\" target=\"_blank\">",
"        2919762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells D, Davies G, and Wagner D, &ldquo;Accidental Injection of Epidural Methohexital,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1987, 67(5):846-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/15/24823/abstract-text/3674498/pubmed\" id=\"3674498\" target=\"_blank\">",
"        3674498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9629 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24823=[""].join("\n");
var outline_f24_15_24823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709039\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194474\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194487\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194475\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194476\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194457\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194441\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194501\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194459\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194505\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194458\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194496\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194506\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194462\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194445\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299690\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194450\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194452\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743972\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743974\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743975\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323384\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6744063\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038677\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194444\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194461\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9629|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/4/17476?source=related_link\">",
"      Methohexital: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/20/40262?source=related_link\">",
"      Methohexital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24824="Patient and renal outcomes in granulomatosis with polyangiitis (Wegeners) and microscopic polyangiitis";
var content_f24_15_24824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24824/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24824/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24824/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24824/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/15/24824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H836147\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with GPA and MPA are treated with initial immunosuppressive therapy (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) to induce remission. This is followed by maintenance immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    to sustain the remission. Although most patients respond to these measures, relapses can occur.",
"   </p>",
"   <p>",
"    Despite the efficacy of immunosuppressive therapy, some patients have appreciable morbidity and some patients die from the disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adverse effects of drug therapy. In addition, some patients develop end-stage renal disease and require renal replacement therapy with dialysis or renal transplantation.",
"   </p>",
"   <p>",
"    Patient and renal outcomes in GPA and MPA will be reviewed here. The clinical manifestations and diagnosis of these disorders, initial and maintenance immunosuppressive therapy, and the management of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -resistant or relapsing disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and MPA are associated with considerable morbidity and mortality that is usually due to one or both of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irreversible organ dysfunction because of inflammatory injury occurring before and during the early phase of effective therapy and during relapses; in addition, scarring can result from healing of inflammatory injury",
"     </li>",
"     <li>",
"      The consequences of prolonged",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggressive immunosuppressive therapy, whether utilized for initial disease, maintenance of remission, or management of relapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of irreversible organ damage and of prolonged (often more than one year) therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids were evaluated in an initial 1992 study from the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/4\">",
"     4",
"    </a>",
"    ]. In this early study, 86 percent of patients had serious morbidity that was due to irreversible vasculitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    side effects of treatment. The principal adverse nonfatal outcomes included glucocorticoid toxicity, an increased risk of malignancy (2.4-fold overall and 33-fold [5.6 percent incidence] for bladder cancer), amenorrhea lasting more than one year (57 percent) or an inability to become pregnant, and progressive organ failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H25#H25\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Treatment-associated toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the later WGET trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    plus standard therapy (glucocorticoids plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or, with limited disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) compared to standard therapy alone, 89 percent of enrolled patients had, within one year of enrollment, at least one sustained adverse effect from either the disease or treatment and, at a mean follow-up of 27 months, 57 percent in both groups had at least one severe or life-threatening adverse effect or died [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/5\">",
"     5",
"    </a>",
"    ]. The major events were cytopenias, infection, heart failure, and venous thrombotic events, including deep venous thromboses and pulmonary emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy have reported similar findings, particularly an association with malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The incidence of bladder cancer, myelodysplasia, and lymphoma due to prolonged cyclophosphamide therapy may be even higher than reported, given the prolonged latent period associated with the development of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H14#H14\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of cancer risk was illustrated in a population-based cohort of 1065 patients with GPA, most of whom were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/7\">",
"     7",
"    </a>",
"    ]. The standardized incidence rate compared to the expected rate in individuals in the general population was 2.0 for all cancers (approximately two new cancers per 100 patient-years of follow-up), 4.8 for bladder cancer (all 14 cases occurred in patients over age 50), 7.3 for squamous skin cancer, 5.7 for leukemia, and 4.2 for lymphoma is approximately seven-fold higher than for individuals without GPA. One caveat with these findings is that the patients were seen between 1969 and 1994 and it is possible that the current cancer rate is lower given the shorter cyclophosphamide induction regimens now in use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another population-based cohort of patients with GPA, the risk of skin cancer correlated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for at least one year and glucocorticoids for at least four years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term survival in patients with GPA and MPA has improved dramatically since the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to the therapeutic regimen, but mortality is still significantly higher than in the general population. Untreated patients have a 90 percent mortality rate within two years. In comparison, different cyclophosphamide studies have reported much lower mortality rates, with large interstudy variation. In different series, the mortality rates have ranged from 12 to 13 percent at 7 to 8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/4,10\">",
"     4,10",
"    </a>",
"    ] to 24 to 44 percent at 4 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of death in GPA are complications from the underlying disease (renal failure, pulmonary failure, and, less often, heart failure and myocardial infarction) and complications that may have been due to therapy (eg, infection and malignancy). Higher mortality rates are observed among the elderly and those who present with florid organ failure, such as patients with diffuse pulmonary hemorrhage requiring ventilatory support or advanced renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/13\">",
"     13",
"    </a>",
"    ]. On the other hand, the presence of relapses does not appear to be a risk factor for mortality (adjusted hazard ratio compared to patients who did not relapse was 1.5 in one series, 95% CI 0.8-2.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate is higher and the major causes of death are different in patients with GPA or MPA who require chronic dialysis compared to those who do not require dialysis. The magnitude of these differences was demonstrated in a series of 523 patients, 136 of whom progressed to end-stage renal disease with follow-up available in 93 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/15\">",
"     15",
"    </a>",
"    ]. Compared to patients who did not progress to end-stage renal disease, patients who developed end-stage renal disease had a significantly higher mortality rate (71 versus 28 percent at five years). One cause of the increase in mortality was infection. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Importance of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renal outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the kidney is a frequent target organ in patients with granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, or MPA, progressive renal failure is commonly observed. In different series with a variable duration of follow-up, end-stage renal disease eventually occurred in 10 to 26 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/4,13,15-19\">",
"     4,13,15-19",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series with a median follow-up of 3.3 years, 136 of 523 patients (26 percent) with ANCA-associated small vessel vasculitis reached end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/15\">",
"       15",
"      </a>",
"      ]. The development of end-stage renal disease was associated with new onset of vasculitis in 51 percent, progressive chronic kidney disease without active vasculitis in 43 percent, and relapsing vasculitis in 6 percent. The patients who developed end-stage renal disease, when compared to those who did not, had a significantly higher peak serum creatinine at presentation (6.9 versus 3.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [610 versus 327",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and were much more likely to be resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      induction therapy (56 versus 8 percent).",
"     </li>",
"     <li>",
"      In a retrospective analysis of 108 patients, the two- and five-year rates of progression to end-stage renal disease were 14 and 25 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study, 12 of 64 patients (19 percent) who were dialysis independent one year after diagnosis became dialysis dependent at a median follow-up of 4.3 years (range 2 to 10 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/13\">",
"       13",
"      </a>",
"      ]. Among 25 patients (29 percent) who were dialysis dependent at diagnosis, two remained dependent and two again became dialysis dependent after less than one year; nine died early without renal recovery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severe renal involvement does NOT preclude the induction of remission or clinically significant improvement in renal function with appropriate therapy as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of newly diagnosed patients, remission was induced in 72 percent of 240 patients with an estimated glomerular filtration rate (eGFR) &le;30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      68 percent of 188 patients with an eGFR &le;20",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      and 57 percent of 96 patients with an eGFR &le;10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/16\">",
"       16",
"      </a>",
"      ]. On the other hand, severe kidney disease at presentation was also a risk factor for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      resistance (odds ratio 1.28 per 1.13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [100",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      elevation in serum creatinine).",
"     </li>",
"     <li>",
"      Among patients who require dialysis during the acute phase of the disease, 55 to 90 percent recover enough function to come off dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/13,16,20-23\">",
"       13,16,20-23",
"      </a>",
"      ], with 40 to 70 percent being maintained off dialysis for three years or more [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The principal determinants of a poor renal outcome include more severe renal dysfunction at presentation, lack of response to initial treatment, renal relapses, age greater than 65 years, and prominent fibrotic changes, such as interstitial fibrosis and glomerulosclerosis on initial renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/4,13,16,25-27\">",
"     4,13,16,25-27",
"    </a>",
"    ]. By comparison, responsiveness to immunosuppressive therapy and improved renal function over time can be observed among patients with predominantly active renal lesions at disease presentation.",
"   </p>",
"   <p>",
"    The importance of some of these risk factors was illustrated in a community-based cohort of 350 patients with a new diagnosis of ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment resistance occurred in 23 percent of treated patients and relapse occurred in 43 percent of patients who attained remission. The proportion of patients who developed end-stage renal disease was significantly higher in those who relapsed compared to those who attained remission and did not relapse (28 percent at 5.5 years versus 19 percent at 9 years, time-adjusted likelihood of progression to end-stage renal disease 4.7). This difference was entirely due to recurrent nephritis, since no patient with nonrenal relapses developed end-stage renal disease.",
"   </p>",
"   <p>",
"    The renal prognosis in this study was much worse in patients who were resistant to initial therapy, as 60 of 76 (79 percent) developed end-stage renal disease at a median of two months after the initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28167042\">",
"    <span class=\"h2\">",
"     Outcomes in elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined outcomes among elderly patients with ANCA-associated vasculitis. This is an important issue since it is unclear whether the benefits of immunosuppression outweigh the risks in this population. One retrospective study examined renal outcome and mortality among patients &gt;80 years old who had biopsy-proven pauci-immune glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/28\">",
"     28",
"    </a>",
"    ]. Ninety-three percent of patients had a positive ANCA, including 72 percent with p-ANCA, 20 percent with c-ANCA and 20 percent who were positive for both p- and c- ANCA. Thirty-four percent of patients had pulmonary involvement. Co-morbid conditions included diabetes (19 percent), congestive heart failure or ischemic heart disease (25 percent), hypertension (78 percent) and malignancy (15 percent). Among 61 patients for whom treatment was known, eleven patients did not receive any immunosuppressive therapy; one and two year outcomes were compared between these patients and the 50 patients who received immunosuppressive therapy (most commonly including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoid);",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      End-stage renal disease was more common in the untreated group at one year (73 versus 36 percent).",
"     </li>",
"     <li>",
"      The 1-year mortality was not different between treated and untreated groups (47 versus 64), but at two years, immunosuppressive therapy was associated with a lower risk for both end-stage renal disease (hazard ratio (HR) 0.17, 95% CI 0.05-0.52) and death (HR 0.33, 95% CI 0.11-0.97).",
"     </li>",
"     <li>",
"      Infections occurred more commonly among the immunosuppressed group (38 versus 9 percent), and mostly included community acquired pneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that end-stage renal disease and overall mortality are quite high in this age group and that immunosuppressive therapy is beneficial but associated with major potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHRONIC RENAL REPLACEMENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known concerning the optimal treatment and outcome of patients GPA or MPA who require maintenance dialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maintenance dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues that need to be addressed in patients on maintenance dialysis: whether to continue immunosuppressive therapy; and the frequency and treatment of relapsing disease. The latter issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H17#H17\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Maintenance dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with GPA or MPA progress to end-stage renal disease and require maintenance dialysis despite initial immunosuppressive and, in some cases, maintenance therapy. Further management varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has NO evidence of active renal disease (ie, absence of hematuria with dysmorphic red cells in the urine sediment, which must be distinguished for isomorphic (normomorphic) hematuria that may be due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -induced bladder injury) and has NO active extrarenal disease, it is unclear how much benefit is provided by usual maintenance therapy to prevent relapse since the rate of relapse is substantially reduced in dialysis. In a review of 452 patients with adequate follow-up information, the relapse rate in the 93 patients who had end-stage renal disease was 0.08 episodes per patient-year, which was significantly lower than the 0.20 episodes per patient-year in the 359 patients without end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"       \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients without active disease who progress to dialysis while on maintenance therapy, we discontinue maintenance therapy in those who have been treated for at least three to six months. Such therapy should be with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      should NOT be given to patients who are on dialysis or have moderate to severe chronic kidney disease.",
"     </li>",
"     <li>",
"      If the patient has NO evidence of active renal disease but continues to have significant active extrarenal disease despite induction immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the patient should be treated for cyclophosphamide-resistant vasculitis, which is discussed elsewhere. Similar considerations apply to the patient with persistent dysmorphic hematuria, with or without extrarenal manifestations. The purpose of continued therapy in patients without extrarenal manifestations is that control of the renal vasculitis might result in enough recovery of renal function to permit the discontinuation of dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"       \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We and other investigators treat chronic dialysis patients with active GPA or MPA the same as those who do not require maintenance dialysis, with the duration of therapy and therapeutic regimen being based upon patient response and whether or not relapse has occurred. Given the increased risk of severe bone marrow suppression in this setting, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should be used cautiously with careful monitoring. Dose adjustment for cyclophosphamide in dialysis patients is not well defined. A suggested approach for oral cyclophosphamide is 50 percent of the usual dose after each hemodialysis session and 75 percent of the usual dose in patients on continuous ambulatory peritoneal dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H23#H23\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Dose modification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    should NOT be used for either remission induction or maintenance therapy in dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Importance of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection occurs at an increased rate and is associated with mortality in patients with GPA or MPA who require chronic dialysis. The magnitude of these effects was demonstrated in a series of 452 patients with adequate follow-up information cited above, 93 of whom progressed to end-stage renal disease and chronic dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection was almost twice as frequent in patients on chronic dialysis who were treated with immunosuppressive therapy compared to patients on chronic dialysis not treated with immunosuppressive therapy (1.9 versus 1.0 episodes per person per year). The sites of infection included the respiratory and urinary tracts, the skin, dialysis access sites, peritonitis, and bacteremia of unknown origin. In addition, infection accounted for a higher proportion of deaths that were due to a known cause in patients on dialysis compared to those with preserved renal function (43 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is only a limited experience with renal transplantation in GPA or MPA. At a minimum, transplantation should be delayed for at least six months from the time of initial presentation or most recent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/29\">",
"     29",
"    </a>",
"    ]. The presence of a positive ANCA at the time of transplantation does not appear to predict recurrence of glomerulonephritis in the transplanted organ. Thus, persistence of isolated ANCA positivity is NOT a contraindication to renal transplantation.",
"   </p>",
"   <p>",
"    It is likely that the immunosuppression administered for the prevention of allograft rejection contributes to the prevention of disease flares among patients with ANCA-associated vasculitis. Issues related to relapsing vasculitis in renal transplant recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H21#H21\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A paucity of data exists concerning the long-term prognosis. In one report, the outcomes of 19 renal transplant recipients with GPA or MPA were compared with 38 matched renal transplant controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/30\">",
"     30",
"    </a>",
"    ]. Both groups had similar actuarial 10 year patient survival (87 and 90 percent in vasculitis and control patients, respectively) and death-censored allograft survival (84 and 100 percent, respectively).",
"   </p>",
"   <p>",
"    Similar findings were noted in a series of 35 renal transplant recipients with GPA or MPA. At five years, overall and death-censored allograft survivals were 94 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24824/abstract/31\">",
"     31",
"    </a>",
"    ]. When these patients were compared to 38 matched control renal transplant recipients without vasculitis, there was no difference between the two groups in the incidence of acute or chronic transplant rejection or arterial hypertension. However, the patients with vasculitis had a significantly higher rate of infection (74 versus 34 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H837437\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), and generally have similar features on renal histology and similar outcomes, although with some differences between these disorders. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term survival in patients with GPA and MPA has improved dramatically since the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      to the therapeutic regimen, but mortality is still significantly higher than in the general population. Untreated patients have a 90 percent mortality rate within two years. In comparison, the mortality rates have ranged from 12 to 13 percent at 7 to 8 years in patients treated with cyclophosphamide. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The morbidity and mortality associated with GPA and MPA are generally due to either irreversible organ dysfunction because of inflammatory injury that occurred prior to effective therapy or during relapse, or to the consequences of prolonged",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggressive immunosuppressive therapy, including malignancy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      infection (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progressive renal failure is commonly observed in patients with GPA or MPA. The principal determinants of a poor renal outcome include more severe renal dysfunction at presentation, lack of response to initial treatment, renal relapses, age greater than 65 years, and prominent fibrotic changes on initial renal biopsy. However, severe renal involvement does NOT preclude the induction of remission or clinically significant improvement in renal function with appropriate therapy. Responsiveness to immunosuppressive therapy and improved renal function over time can be observed among patients with predominantly active renal lesions at disease presentation. &nbsp;(See",
"      <a class=\"local\" href=\"#H5\">",
"       'Renal outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with GPA or MPA progress to end-stage renal disease and require maintenance dialysis despite initial immunosuppressive and maintenance therapy. Management of immunosuppressive therapy varies with the clinical setting:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who have no evidence of active disease who progress to dialysis while on maintenance therapy, we discontinue maintenance therapy in those who have been treated for at least three to six months. Such therapy should be with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      should NOT be given to patients who are on dialysis or have moderate to severe chronic kidney disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient has NO evidence of active renal disease but continues to have significant active extrarenal disease despite induction immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the patient should be treated for cyclophosphamide-resistant vasculitis. Treatment regimens are discussed elsewhere. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"       \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient has persistent dysmorphic hematuria, with or without extrarenal manifestations despite induction immunosuppressive therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the patient should be treated for cyclophosphamide-resistant vasculitis. The purpose of continued therapy in patients without extrarenal manifestations is that control of the renal vasculitis might result in enough recovery of renal function to permit the discontinuation of dialysis. Treatment regimens are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"       \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We and other investigators treat chronic dialysis patients with active GPA or MPA the same as those who do not require maintenance dialysis, with the duration of therapy and therapeutic regimen being based upon patient response and whether or not relapse has occurred. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Given the increased risk of severe bone marrow suppression in this setting, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      should be used cautiously with careful monitoring. Dose adjustment for cyclophosphamide in dialysis patients is not well defined. A suggested approach for oral cyclophosphamide is 50 percent of the usual dose after each hemodialysis session and 75 percent of the usual dose in patients on continuous ambulatory peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link&amp;anchor=H23#H23\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Dose modification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      should NOT be used for either remission induction or maintenance therapy in dialysis patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Maintenance dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection occurs at an increased rate and is associated with mortality in patients with GPA or MPA who require chronic dialysis. Common sites of infection include the respiratory and urinary tracts, the skin, dialysis access sites, peritonitis, and bacteremia of unknown origin. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Importance of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is limited experience with renal transplantation in GPA or MPA. Transplantation should be delayed for at least six months from the time of initial presentation or most recent relapse. The persistence of isolated ANCA positivity is NOT a contraindication to renal transplantation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/4\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/5\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/6\">",
"      Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/7\">",
"      Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002; 100:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/8\">",
"      Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/9\">",
"      Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/10\">",
"      Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/11\">",
"      Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/12\">",
"      Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/13\">",
"      Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003; 63:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/14\">",
"      Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/15\">",
"      Lionaki S, Hogan SL, Jennette CE, et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 2009; 76:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/16\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/17\">",
"      Weidner S, Geuss S, Hafezi-Rachti S, et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/18\">",
"      Aasar&oslash;d K, Iversen BM, Hammerstr&oslash;m J, et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000; 15:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/19\">",
"      Aasar&oslash;d K, Bostad L, Hammerstr&oslash;m J, et al. Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001; 16:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/20\">",
"      Mekhail TM, Hoffman GS. Longterm outcome of Wegener's granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 2000; 27:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/21\">",
"      Glassock RJ. Intensive plasma exchange in crescentic glomerulonephritis: help or no help? Am J Kidney Dis 1992; 20:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/22\">",
"      Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/23\">",
"      Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/24\">",
"      Geffriaud-Ricouard C, No&euml;l LH, Chauveau D, et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/25\">",
"      Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/26\">",
"      Neumann I, Kain R, Regele H, et al. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 2005; 20:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/27\">",
"      Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/28\">",
"      Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int 2011; 79:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/29\">",
"      Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int 1999; 56:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/30\">",
"      Moroni G, Torri A, Gallelli B, et al. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant 2007; 7:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24824/abstract/31\">",
"      Gera M, Griffin MD, Specks U, et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 2007; 71:1296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3094 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24824=[""].join("\n");
var outline_f24_15_24824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H837437\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H836147\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renal outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28167042\">",
"      Outcomes in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHRONIC RENAL REPLACEMENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Importance of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H837437\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=related_link\">",
"      Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24825="Breast masses and other common breast problems";
var content_f24_15_24825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast masses and other common breast problems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24825/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/15/24825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of breast complaints requires a vigilant and systematic approach to ensure that cancers are diagnosed and treated promptly and benign breast disease receives appropriate attention and care. The missed diagnosis of breast cancer is one of the most frequent causes of malpractice claims in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The majority of malpractice awards involve women who presented with a breast complaint in whom the diagnosis of cancer was delayed because of a negative clinical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mammogram [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the vast majority of breast masses and breast complaints are caused by benign breast disease, even in referral practices. In one breast clinic, breast cancer accounted for 10 percent of breast complaints in referred patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/6\">",
"     6",
"    </a>",
"    ]; the most common diagnoses were cysts and fibroadenomas.",
"   </p>",
"   <p>",
"    The diagnostic approach, clinical features, and initial evaluation of women with breast complaints will be reviewed here. The classification and treatment of these disorders and screening average risk women for breast cancer are discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation of a breast complaint begins with a thorough history and physical examination. Breast disease may present with a palpable breast mass or thickening, change in the size or appearance of the breast, breast pain, skin changes, nipple discharge or inversion, or as an asymptomatic abnormal finding on a screening mammogram [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a breast complaint, the history has two primary components: a detailed history of the patient's concerns and documentation of the patient's risk factors for developing breast cancer. A full medical and surgical history, including medications and allergies, should also be obtained. The patient's subjective information about how and when the symptom was first noted and how it changed over time should be recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Presenting symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of presenting symptoms should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any change in the general appearance of the breast, such as an increase or decrease in size, a change in symmetry",
"     </li>",
"     <li>",
"      New or persistent skin changes",
"     </li>",
"     <li>",
"      New nipple inversion",
"     </li>",
"     <li>",
"      If nipple discharge is present, whether it is bilateral, unilateral or from one specific duct. Other important information includes the timing, color, frequency and spontaneity of the discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"       \"Nipple discharge\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The characteristics of any breast pain, the relationship of symptoms to menstrual cycles (cyclic or non-cyclic), the location within the breast (or both breasts), the duration and whether it is aggravated or alleviated by any activities or medications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"       \"Breast pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a breast mass and its evolution, including how it was first noted (accidentally, by breast self-examination, clinical breast examination, or mammogram), how long it has been present and whether it has changed in size. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Breast masses'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The precise location of any breast mass. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Documentation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Whether a mass waxes and wanes during the menstrual cycle. Benign cysts may be more prominent premenstrually and regress in size during the follicular phase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"       \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for the development of breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough risk assessment is part of the evaluation of women with breast complaints, and significant negative as well as positive findings should be documented in the medical record (",
"    <a class=\"graphic graphic_table graphicRef64508 \" href=\"UTD.htm?15/52/16205\">",
"     table 1",
"    </a>",
"    ). However, only 50 percent of breast cancers occur in women with identifiable risk factors other than age, underscoring the need to approach every breast complaint thoughtfully [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ]. Risk factors for breast cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link&amp;anchor=H22#H22\">",
"     \"Breast development and morphology\", section on 'Parity, lobular differentiation and breast cancer risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gender and age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factors for breast cancer are female gender and increasing age. The incidence of breast cancer increases with age, so while any new breast complaint should be fully investigated, a new finding in a woman over 50 raises increased suspicion. In contrast, a new breast complaint in a woman less than 30 is highly likely to be benign.",
"   </p>",
"   <p>",
"    Men can also develop breast cancer, but at a much lower rate than women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of breast cancer elevates the breast cancer risk. Both maternal and paternal history of breast cancer is relevant. A history of male breast cancer in the family is a red flag for the presence of a gene mutation. Additional clues that a gene mutation may be present are a history of breast cancer in young women in the family, bilateral breast cancers, a history of ovarian cancer in the family and multiple relatives with cancers. The family history should document all cancers, and not just focus on breast or ovarian cancer. While relatively rare, a proven mutation in the patient or a family member with the BRCA1 or BRCA2 gene (hereditary breast-ovarian cancer syndrome) indicates a high risk for the development of multiple benign or malignant breast lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Other, less-common genetic syndromes that confer elevated breast cancer risk are Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, ataxia-telangiectasia heterozygosity, and hereditary diffuse gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462459902#H462459902\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Cowden syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"     \"Li-Fraumeni syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reproductive history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman's age at menarche, last menstrual period and whether menses are irregular, number of pregnancies and age at first full-term delivery and age at menopause should be recorded. Women who have early menarche, nulliparity or older age at first full-term pregnancy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    late menopause are at slightly higher risk of developing breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     History of estrogen supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk is also elevated by a history of diethylstilbestrol (DES) exposure in utero and by postmenopausal hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=see_link\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol intake of more than one drink a day can also increase the likelihood of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/16\">",
"     16",
"    </a>",
"    ]. A standard drink contains about 10 grams of alcohol, and consumption of each additional 10 grams of alcohol a day is associated with a 9 percent increase in the risk of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Breast density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased breast density on mammograms has also been identified as a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Prior biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's personal breast history is important information to gather when both assessing a new complaint and estimating risk. A prior history of breast cancer is one of the strongest risk factors for developing a new breast cancer. The number of breast biopsies a woman has had, and, more importantly, the results of those biopsies, are also associated with increased risk. Prior abnormal breast biopsies showing atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS) elevate the risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calculating risk of developing breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a calculator is helpful for framing the patient's risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/21\">",
"     21",
"    </a>",
"    ]. The most commonly used risk calculator model is the Gail model; however, several others, such as the Claus model and Tyrer-Cuzick model, have been proposed in an effort to develop the most accurate predictor of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Gail model remains the most useful of these, and is a mathematical model to calculate risk of developing breast cancer, and is based upon the age, menarche, reproductive history, family history in first-degree relatives and prior biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/24\">",
"     24",
"    </a>",
"    ]; the tool can be accessed online at",
"    <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"     www.cancer.gov/bcrisktool/",
"    </a>",
"    . It should be noted that the Gail model has the potential to underestimate breast cancer risk for women with a very strong family history of breast or ovarian cancer that does not involve first-degree relatives (as is often the case with a paternal lineage). A full family history is essential, and if this raises suspicion of a genetic risk, alternative risk projection strategies should be utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Calculating risk of gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a strong family history of breast cancer, the BRCAPRO model is used to calculate the risk of having a BRCA gene mutation. This is often used to help counsel women about whether to have gene testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast examination includes the neck, chest wall, both breasts, and axillae, and is part of a full physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/7,25,26\">",
"     7,25,26",
"    </a>",
"    ]. The breast examination is best performed when hormonal stimulation of the breasts is minimized, which is usually seven to nine days after the onset of menses in premenopausal women. The timing of the breast examination is not important in postmenopausal women, or premenopausal women who are taking birth control pills or other treatments that affect ovarian suppression.",
"   </p>",
"   <p>",
"    There can be a great deal of anxiety and embarrassment associated with the breast examination. Attention to modesty is important and a kind, gentle manner and touch will help put the patient at ease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be examined in both the upright and supine positions. The patient must be disrobed from the waist up allowing the examiner to visualize and inspect the breasts. The breast examination is started with the patient in a seated position with her arms relaxed. The patient is then asked to raise her arms over her head so the lower part of the breasts can be inspected. Finally, the patient should put her hands on her hips and press in to contract the pectoral muscles so that any other areas of retraction can be visualized. Carefully inspect for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymmetry - Observe the breast outline and contour for any bulging areas.",
"     </li>",
"     <li>",
"      Skin changes - Check for dimpling or retraction, edema, ulceration, erythema, or eczematous appearance, such as scaly, thickened, raw skin.",
"     </li>",
"     <li>",
"      Nipples - Assess for symmetry, inversion or retraction, nipple discharge or crusting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After careful inspection, ask the patient for permission to proceed with the palpation of regional lymph nodes and the breasts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regional lymph node examination - While the patient is sitting, the regional lymph nodes are examined, with attention to the cervical, supraclavicular, infraclavicular, and axillary nodal basins. The best examination of the axillary nodes requires that the patient relax her shoulders and allow the examiner to support her arm while the axilla is palpated. It is important to note the presence of any palpable nodes and their characteristics, whether they are soft and mobile or firm, hard, tender, fixed, or matted (",
"      <a class=\"graphic graphic_figure graphicRef61035 \" href=\"UTD.htm?29/28/30152\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Breast examination - A bimanual examination of the breasts should then be performed while the patient is still in the sitting position, supporting the breast gently with one hand and examining the breast with the other hand. The examination is then completed with the patient in a supine position, with the ipsilateral arm raised above her head. This allows the examiner to flatten the breast tissue against the patient's chest. It is sometimes useful to have the patient roll onto her contralateral hip to flatten the lateral part of the breast.",
"      <br/>",
"      <br/>",
"      The entire breast must be examined, including the breast tissue that comprises the axillary tail of Spence, which extends laterally toward the axilla. To be sure that all breast tissue is included in the examination, it is best to cover a rectangular area bordered by the clavicle superiorly, the midsternum medially, the midaxillary line laterally, and the lower rib cage inferiorly (",
"      <a class=\"graphic graphic_figure graphicRef61035 \" href=\"UTD.htm?29/28/30152\">",
"       figure 1",
"      </a>",
"      ). The examination technique should be systematic, using either concentric circles, a radial approach or vertical strips, referred to as the \"lawnmower\" method [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. Palpation should be done with the fingerpads rather than the fingertips. Circular motions with light, medium and deep pressure ensure palpation of all levels of breast tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/25,28\">",
"       25,28",
"      </a>",
"      ]. One hand stabilizes the breast while the other hand is used for the examination [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the patient's concern as well as any abnormality found on examination should be documented. The size of any mass should be measured in centimeters with a tape measure, and its location, mobility, and consistency recorded. It is helpful to record the location of any abnormality by documenting both the position on the breast and the distance in centimeters from the areola. In this manner, the precise location can be easily identified on subsequent follow-up examinations, by the initial examiner as well as other practitioners. The \"clock\" system can be used for documentation, comparing the breast to a clock and using the location on the clock to indicate the location of a lesion (eg, 1 o'clock position). The entire examination should be clearly and completely documented in detail, including significant negatives, even if it is completely normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BREAST MASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient complaints of a breast mass are common. Fibroadenomas and cysts are the most common causes of benign breast masses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/7\">",
"     7",
"    </a>",
"    ]. Although 90 percent or more of palpable breast masses in women in their 20s to early 50s are benign, excluding breast cancer is a crucial step in the assessment of these masses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/29\">",
"     29",
"    </a>",
"    ]. Older age, previous history of breast cancer, and family history in a first-degree relative have all been shown to increase the chance that a palpable breast mass is cancerous on biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, 16 percent of women ages 40 to 69 sought physician advice about breast complaints over a 10-year period for a rate of 23 visits per 1000 woman years; in 40 percent, the complaint was for a breast mass or nodularity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/30\">",
"     30",
"    </a>",
"    ]. Breast cancer was found in 11 percent of women complaining of a mass (and 4 percent of women with any breast complaint) in this study. Thus, clinicians should pursue to resolution all breast complaints and abnormalities, regardless of the mode of presentation.",
"   </p>",
"   <p>",
"    Findings in benign breast disease can mimic those in cancer, since normal breast tissue in women is often somewhat nodular. The first goal of the physical examination is to determine whether a dominant mass, thickening, or asymmetry is present. This is particularly important in younger women, whose breasts are more likely to be generally nodular than in older women. In a study of 600 women under the age of 40 years who were referred to a breast clinic for evaluation of breast mass, only about one-third were found to have a dominant mass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/31\">",
"     31",
"    </a>",
"    ]. A second opinion should be sought if the primary care clinician is unsure about the presence of a dominant mass.",
"   </p>",
"   <p>",
"    If the initial physical examination does not confirm the presence of a dominant mass, thickening or asymmetry, close observation with a follow-up examination in two to three months should be arranged to assure resolution or stability of findings. Alternatively, the patient can be referred to a breast clinic, depending on the confidence and expertise of the examiner.",
"   </p>",
"   <p>",
"    A number of \"classic\" characteristics of cancerous lesions have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Single lesion",
"     </li>",
"     <li>",
"      Hard",
"     </li>",
"     <li>",
"      Immovable",
"     </li>",
"     <li>",
"      Irregular borders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, physical findings individually do not distinguish well between cancers and benign lesions. In one study, for example, single lesions were the presenting feature in the same percentage of women ultimately diagnosed with benign or malignant disease on biopsy (91 percent), and a substantial percentage of malignant lesions were soft or cystic (38 percent), freely movable (61 percent), regular (41 percent), and less than 2 cm in size (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have examined the usefulness of the physical examination for diagnosing benign versus malignant breast masses have found that clinicians can often make the right diagnosis, but not to a degree that is sufficiently reassuring to the clinician or patient. In one report, from a study of symptomatic women, experienced examiners who diagnosed \"definite cancer\" on palpation were correct in 93 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/34\">",
"     34",
"    </a>",
"    ]. In another series of referred patients, the physical examination had a positive predictive value of 73 percent and a negative predictive value of 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, while the history and physical examination are important first steps in the assessment of a breast mass, the evaluation does not stop there. Next steps may include ultrasound, mammography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy, depending upon the findings from the history and physical examination, patient age and preferences, and the local expertise of surgeons, radiologists, and pathologists (",
"    <a class=\"graphic graphic_algorithm graphicRef68561 \" href=\"UTD.htm?20/8/20610\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mammogram should be the first diagnostic test ordered in a woman over the age of 30 with a new breast complaint. Even if the patient had a recent negative screening mammogram, if they have a focal complaint, a diagnostic mammogram should be obtained.",
"   </p>",
"   <p>",
"    Mammography is not routinely ordered in women under age 30 years. However, it is not inappropriate to order a mammogram as part of a diagnostic evaluation of a clinically suspicious mass in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/8\">",
"     8",
"    </a>",
"    ]. Although younger women have denser breast tissue, abnormalities can still be detected with mammograms in this age group. Digital mammography is superior to film screen mammography in premenopausal women and women with dense breasts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain mammographic features such as asymmetry, clustered pleomorphic calcification, increasing density, or a new mass with irregular borders or spiculation are suggestive of malignancy. However, mammography cannot determine whether a mass is benign. In a study of 41,427 diagnostic mammograms, the sensitivity and specificity of diagnostic mammography in women not reporting a breast mass were 82.3 and 91.2 percent respectively; in women with a self-reported breast mass, the sensitivity and specificity were 87.3 and 84.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A normal mammogram does not eliminate the need for further evaluation of a suspicious mass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/8\">",
"     8",
"    </a>",
"    ]. Mammography misses 10 to 20 percent of clinically palpable breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Thus, a negative mammogram should not stop further investigation if a suspicious mass is felt on clinical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targeted ultrasonography is a useful diagnostic test to evaluate a palpable mass or an area of abnormality detected on mammogram. It is particularly useful for assessing whether a mass is solid or cystic in nature.",
"   </p>",
"   <p>",
"    Ultrasound is the first line of imaging in a woman who is pregnant or less than 30 years old with focal breast symptoms or findings. Ultrasonography is also used to provide guidance for biopsies and other interventions. If the mass is a cyst, it can be aspirated if symptomatic. If the mass is solid and has the characteristics of a benign fibroadenoma, then either short-term observation or biopsy can be offered to the patient. If the mass is not classic for either a cyst or a fibroadenoma, then biopsy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast magnetic resonance imaging (MRI) is not indicated for the work-up of an undiagnosed mass. MRI is best reserved for diagnostic dilemmas and used with discretion as there is a significant false positive rate, which dramatically increases the rate of benign biopsies.",
"   </p>",
"   <p>",
"    Diagnostic breast MRIs should only be performed in institutions that have capacity for MRI directed biopsy, as lesions seen on MRI may not be visible on other imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An MRI machine with a dedicated breast coil is employed for the test, and gadolinium dye is injected intravenously before the procedure. The dye can cause serious reactions in patients with underlying renal disease (nephrogenic systemic fibrosis and worsening renal failure). Baseline BUN and creatinine are routinely checked before the test is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many discrete palpable abnormalities are simple breast cysts and will need only confirmation with an ultrasound; needle aspiration should be performed if the cysts are symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"     \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Masses that are solid on ultrasound imaging will require biopsy to exclude cancer and provide a histological diagnosis. Normal imaging should not be considered proof that malignancy is not present [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic procedure of choice for most solid masses is core needle biopsy rather than surgical biopsy. Biopsy approaches are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Triple test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triple test or assessment refers to the concurrent use of physical examination, mammography, and needle biopsy for diagnosing palpable breast mass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/41\">",
"     41",
"    </a>",
"    ]. Either a fine needle aspiration biopsy (FNAB) or core biopsy can be employed. However, successful FNAB requires experienced cytopathologists. In institutions where experienced cytopathologists are not available, the initial diagnostic procedure of choice should be core needle biopsy (CNB) rather than FNA. Very few breast cancers are missed using the triple test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast masses cause anxiety in most patients. Support and careful communication are essential.",
"   </p>",
"   <p>",
"    It is important that women understand the outcome of each diagnostic test and that none is 100 percent sensitive or specific. Women found to have benign conditions should be encouraged to contact their clinician if problems recur. Women who are found to have solid masses that are not suspicious after evaluation with fine needle or core needle biopsy, but that are not excised, need careful follow-up since both biopsies are occasionally falsely negative for cancer.",
"   </p>",
"   <p>",
"    An expedient evaluation is important to relieve anxiety, although diagnosing breast cancer is not a medical emergency. There are conflicting data regarding the importance of three to six month delays in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. This contradiction may be explained by the source of the delay; it is likely that patient delays contribute more to decreased breast cancer survival than provider delays [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER COMMON BREAST PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to breast masses, other common problems related to the breast are breast pain, nipple discharge, skin changes, or an abnormal mammogram.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Breast pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast pain is a common and nonspecific symptom. However, localized breast pain is the only presenting symptom in up to 15 percent of women with newly diagnosed breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/30,45-47\">",
"     30,45-47",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"     \"Breast pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast pain has traditionally been attributed to fibrocystic changes, fibrocystic breast disease, chronic cystic mastitis, and mammary dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. However, breast pain and nodularity are so common that the term \"fibrocystic breast disease\" is inaccurate, and these symptoms are usually a normal response to hormonal changes during the menstrual cycle. From a clinical standpoint, terminology that describes the breast examination accurately, such as \"nodular, sensitive breast,\" is more accurate and avoids identifying normal physiologic changes as \"disease.\"",
"   </p>",
"   <p>",
"    Similarly, the term fibrocystic change has been used by pathologists to refer to a variety of histologic findings, such as fibrosis, ductal hyperplasia and adenosis. To describe benign breast disorders more accurately, histologic findings are now categorized into one of three categories, using strictly defined categories that correlate with the risk of developing breast cancer: nonproliferative lesions, proliferative lesions without atypia, and atypical hyperplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral or milky discharge (galactorrhea) is benign and most commonly occurs after childbearing. Generally, galactorrhea subsides within one year after cessation of nursing, but occasionally lasts longer. Galactorrhea may also be associated with hypothyroidism, and prolactin-producing pituitary tumors as well as certain medications, such as antipsychotics and tricyclic antidepressants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous, clear, colored, or bloody unilateral uniductal nipple discharge is suspicious and requires investigation. Discharge that is only seen with stimulation is generally not worrisome, and will usually stop if the patient is encouraged to stop stimulation. While nipple discharge may be due to benign conditions such as a papilloma, cystic changes in the breast, or duct ectasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83698 \" href=\"UTD.htm?11/63/12278\">",
"     image 1",
"    </a>",
"    ), it may also be due to papillary cancer or ductal carcinoma in situ and full work-up is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic approach to nipple discharge is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nipple inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nipple is the central projection in the areola. When the nipple is pulled in and points inward instead of out, it is termed nipple inversion or retraction (",
"    <a class=\"graphic graphic_picture graphicRef80978 \" href=\"UTD.htm?5/23/5489\">",
"     picture 1",
"    </a>",
"    ). Nipple inversion can affect one breast or both, and can be congenital or acquired. Acquired nipple inversion can be due to benign or malignant causes. Benign nipple inversion is usually a gradual process, occurring over a few years. When nipple inversion occurs rapidly, the underlying cause can be mammary duct ectasia, postsurgical changes, periductal mastitis, fat necrosis, or an underlying malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/56\">",
"     56",
"    </a>",
"    ]. A complete breast examination and radiologic evaluation with mammogram and ultrasound should be performed to look for the underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Skin changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any skin lesion can be found on the skin of the breast, but the most common complaints are skin discoloration, eczematous changes such as scaling, ulceration or crusting, skin dimpling, thickening, or edema.",
"   </p>",
"   <p>",
"    Redness associated with pain and swelling is seen with mastitis or infected skin lesions, such as epidermal inclusion cysts. If the skin changes are associated with tenderness and an underlying fluctuance more consistent with infection, empiric treatment with antibiotics can be initiated with follow-up to make sure there is appropriate response. If the infection does not respond to antibiotics alone, ultrasound evaluation along with needle aspiration and culture to guide treatment is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=see_link\">",
"     \"Breast abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=see_link\">",
"     \"Erythematous disorders of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Redness and ulceration of the skin around the nipple can be seen in Paget disease, which is associated with underlying malignancy, often without an associated breast mass or mammographic abnormality (",
"    <a class=\"graphic graphic_picture graphicRef62378 \" href=\"UTD.htm?18/63/19444\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75186 \" href=\"UTD.htm?6/27/6584\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/57\">",
"     57",
"    </a>",
"    ]. Erythema associated with skin thickening or edema is worrisome for inflammatory breast cancer (",
"    <a class=\"graphic graphic_picture graphicRef61430 \" href=\"UTD.htm?28/29/29137\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60937 \" href=\"UTD.htm?6/42/6831\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A skin punch biopsy can be performed in the office with local anesthesia to differentiate between benign and malignant skin changes. A diagnostic mammogram should be performed to rule out an underlying malignancy in women over 30.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Abnormal mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women have an abnormality diagnosed on screening mammogram and have no physical complaints or findings. The radiologist will indicate whether the abnormality requires follow-up, additional imaging or biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the abnormality is a mass, an ultrasound is performed to see if the abnormality is cystic or solid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83699 \" href=\"UTD.htm?42/54/43877\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/59\">",
"     59",
"    </a>",
"    ]. The radiologist can usually perform an aspiration for a cystic lesion or core biopsy of a solid lesion with ultrasound guidance. A clip should always be placed to guide any subsequent surgery that may be required if the biopsy is positive. The clip also provides confirmation that the proper area on the mammogram was targeted for biopsy.",
"   </p>",
"   <p>",
"    If the abnormality is a cluster of suspicious calcifications, a core biopsy under stereotactic biopsy may be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24825/abstract/60\">",
"     60",
"    </a>",
"    ]. However, surgical biopsy may be needed if the abnormality cannot be safely or accurately biopsied with a core biopsy under radiologic guidance, or if the needle biopsy is not concordant with the imaging appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       \"Patient information: Common breast problems (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       \"Patient information: Common breast problems (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is important to evaluate breast complaints thoroughly to ensure that breast cancers, as well as benign breast lesions, are diagnosed and treated promptly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of the woman with a breast problem requires careful assessment of her presenting symptoms and risks of developing breast cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination of the breasts and regional lymph nodes includes inspection and palpation. Documentation should include significant negatives as well as any positive findings. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with breast problems can present with an abnormal mammogram or any combination of symptoms, including breast mass or thickening, breast pain, nipple discharge or skin changes (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Other common breast problems'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Negative imaging should not stop further investigation if a suspicious mass is felt on clinical examination. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many discrete palpable abnormalities are simple breast cysts and will need only confirmation with an ultrasound; needle aspiration should be performed if the cysts are symptomatic. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Masses that are solid on ultrasound imaging will require biopsy to exclude cancer and provide a histological diagnosis. Normal imaging should not be considered proof that malignancy is not present. The diagnostic procedure of choice for most solid masses is core needle biopsy rather than surgical biopsy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast masses cause anxiety in most patients. Support and careful communication are essential. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Physician Insurers Association of America. Breast cancer study, 3rd edition, Physician Insurers Association of America, Rockville 2002. file://www.neomatrix.com/pdfs/PIAAStudy.pdf (Accessed on January 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/2\">",
"      Singh H, Sethi S, Raber M, Petersen LA. Errors in cancer diagnosis: current understanding and future directions. J Clin Oncol 2007; 25:5009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/3\">",
"      Gandhi TK, Kachalia A, Thomas EJ, et al. Missed and delayed diagnoses in the ambulatory setting: a study of closed malpractice claims. Ann Intern Med 2006; 145:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/4\">",
"      Mitnick JS, Vazquez MF, Kronovet SZ, Roses DF. Malpractice litigation involving patients with carcinoma of the breast. J Am Coll Surg 1995; 181:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/5\">",
"      Kern KA. Causes of breast cancer malpractice litigation. A 20-year civil court review. Arch Surg 1992; 127:542.",
"     </a>",
"    </li>",
"    <li>",
"     Donegan, WL. Diagnosis. In: Cancer of the breast, Donegan, WL, Spratt, JS (Eds), WB Saunders, Philadelphia 1995. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/7\">",
"      Morrow M. The evaluation of common breast problems. Am Fam Physician 2000; 61:2371.",
"     </a>",
"    </li>",
"    <li>",
"     Cady, B, Steele, GD, Morrow, M, et al. Evaluation of Common Breast Problems: A Primer for Primary Care Providers; prepared by the Society of Surgical Oncology and the Commission on Cancer of the American College of Surgeons for the Centers for Disease Control and Prevention, Publication no. 633-001/20900, US Department of Health and Human Services, 1998. www.utmb.edu/Surgery/clerks/primer.htm (Accessed on August 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/9\">",
"      Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/10\">",
"      Ozanne EM, Klemp JR, Esserman LJ. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J 2006; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/11\">",
"      Morrow M. Identification of the woman at risk for breast cancer: problem solved? Recent Results Cancer Res 1999; 151:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/12\">",
"      Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003; 97:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/13\">",
"      Nusbaum, R, Vogel, KJ, Ready, K. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis 2006-2007; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/14\">",
"      Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/15\">",
"      Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008; 100:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/16\">",
"      Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001; 286:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/17\">",
"      Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer 2007; 109:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/18\">",
"      Ginsburg OM, Martin LJ, Boyd NF. Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 2008; 99:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/19\">",
"      Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/20\">",
"      Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/21\">",
"      Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J 2001; 7:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/22\">",
"      Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/23\">",
"      Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/24\">",
"      Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/25\">",
"      Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999; 282:1270.",
"     </a>",
"    </li>",
"    <li>",
"     Morrow, M. Physical examination of the breast. In: Breast diseases, 3rd edition, Harris, JR, et al (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2004. p.29.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/27\">",
"      Saunders KJ, Pilgrim CA, Pennypacker HS. Increased proficiency of search in breast self-examination. Cancer 1986; 58:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/28\">",
"      Hall DC, Goldstein MK, Stein GH. Progress in manual breast examination. Cancer 1977; 40:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/29\">",
"      Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/30\">",
"      Barton MB, Elmore JG, Fletcher SW. Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med 1999; 130:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/31\">",
"      Morrow M, Wong S, Venta L. The evaluation of breast masses in women younger than forty years of age. Surgery 1998; 124:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/32\">",
"      The palpable breast lump: information and recommendations to assist decision-making when a breast lump is detected. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Canadian Association of Radiation Oncologists. CMAJ 1998; 158 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/33\">",
"      Venet L, Strax P, Venet W, Shapiro S. Adequacies and inadequacies of breast examinations by physicians in mass screening. Cancer 1971; 28:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/34\">",
"      Rimsten A, Stenkvist B, Johanson H, Lindgren A. The diagnostic accuracy of palpation and fine-needle biopsy and an evaluation of their combined use in the diagnosis of breast lesions: report on a prospective study in 1244 women with symptoms. Ann Surg 1975; 182:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/35\">",
"      van Dam PA, Van Goethem ML, Kersschot E, et al. Palpable solid breast masses: retrospective single- and multimodality evaluation of 201 lesions. Radiology 1988; 166:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/36\">",
"      Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/37\">",
"      Barlow WE, Lehman CD, Zheng Y, et al. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst 2002; 94:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/38\">",
"      Cahill CJ, Boulter PS, Gibbs NM, Price JL. Features of mammorgraphically negative breast tumours. Br J Surg 1981; 68:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/39\">",
"      Donegan WL. Evaluation of a palpable breast mass. N Engl J Med 1992; 327:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/40\">",
"      Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 26:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/41\">",
"      Clarke D, Sudhakaran N, Gateley CA. Replace fine needle aspiration cytology with automated core biopsy in the triple assessment of breast cancer. Ann R Coll Surg Engl 2001; 83:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/42\">",
"      Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999; 353:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/43\">",
"      Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet 1999; 353:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/44\">",
"      Coates AS. Breast cancer: delays, dilemmas, and delusions. Lancet 1999; 353:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/45\">",
"      Preece PE, Baum M, Mansel RE, et al. Importance of mastalgia in operable breast cancer. Br Med J (Clin Res Ed) 1982; 284:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/46\">",
"      BeLieu RM. Mastodynia. Obstet Gynecol Clin North Am 1994; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/47\">",
"      Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain. Mayo Clin Proc 2004; 79:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/48\">",
"      Love SM, Gelman RS, Silen W. Sounding board. Fibrocystic \"disease\" of the breast--a nondisease? N Engl J Med 1982; 307:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/49\">",
"      Devitt JE. Abandoning fibrocystic disease of the breast: timely end of an era. CMAJ 1986; 134:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/50\">",
"      Hutter RV. Goodbye to \"fibrocystic disease\". N Engl J Med 1985; 312:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/51\">",
"      Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/52\">",
"      Hughes LE, Mansel RE, Webster DJ. Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 1987; 2:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/53\">",
"      Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985; 55:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/54\">",
"      Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 1992; 23:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/55\">",
"      Leis HP Jr, Greene FL, Cammarata A, Hilfer SE. Nipple discharge: surgical significance. South Med J 1988; 81:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/56\">",
"      Da Costa D, Taddese A, Cure ML, et al. Common and unusual diseases of the nipple-areolar complex. Radiographics 2007; 27 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/57\">",
"      Thiers BH. Dermatologic manifestations of internal cancer. CA Cancer J Clin 1986; 36:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/58\">",
"      Liberman L, Menell JH. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am 2002; 40:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/59\">",
"      Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D. Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med 2003; 139:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24825/abstract/60\">",
"      Fajardo LL, Pisano ED, Caudry DJ, et al. Stereotactic and sonographic large-core biopsy of nonpalpable breast lesions: results of the Radiologic Diagnostic Oncology Group V study. Acad Radiol 2004; 11:293.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 804 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24825=[""].join("\n");
var outline_f24_15_24825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Presenting symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for the development of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gender and age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reproductive history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - History of estrogen supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Breast density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Prior biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calculating risk of developing breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Calculating risk of gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BREAST MASSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Breast MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Triple test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER COMMON BREAST PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Skin changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Abnormal mammogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/804|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/8/20610\" title=\"algorithm 1\">",
"      Breast mass algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/804|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/63/12278\" title=\"diagnostic image 1\">",
"      Breast duct ectasia MRI image",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/54/43877\" title=\"diagnostic image 2\">",
"      Breast clustered cysts mammogram and ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/804|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/28/30152\" title=\"figure 1\">",
"      Breast exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/42/6831\" title=\"figure 2\">",
"      Edema skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/804|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/23/5489\" title=\"picture 1\">",
"      Nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/63/19444\" title=\"picture 2\">",
"      Paget disease nipple A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/27/6584\" title=\"picture 3\">",
"      Paget disease nipple B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/29/29137\" title=\"picture 4\">",
"      Locally advanced BC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/52/16205\" title=\"table 1\">",
"      Risk factors breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=related_link\">",
"      Breast cysts: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=related_link\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=related_link\">",
"      Inflammatory breast cancer: Clinical features and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24826="Overview of the treatment of bleeding peptic ulcers";
var content_f24_15_24826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of bleeding peptic ulcers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24826/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24826/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/15/24826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/15/24826/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/15/24826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal (UGI) bleeding secondary to peptic ulcer disease is a common medical condition that results in high patient morbidity and medical care costs. While the majority of patients with bleeding peptic ulcers will stop bleeding spontaneously and not rebleed during hospitalization, a subgroup of patients is at high-risk for recurrent hemorrhage and requires endoscopic therapy to decrease this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/1\">",
"     1",
"    </a>",
"    ]. If endoscopic therapy fails, interventional angiography or surgery may be required.",
"   </p>",
"   <p>",
"    The pharmacologic and endoscopic management of UGI bleeding due to peptic ulcer disease will be reviewed here. The discussion that follows is consistent with a multidisciplinary international consensus statement published in 2010, a 2012",
"    <a class=\"external\" href=\"file://www.asge.org/WorkArea/showcontent.aspx?id=15156\">",
"     guideline",
"    </a>",
"    issued by the American Society for Gastrointestinal Endoscopy, and a 2012",
"    <a class=\"external\" href=\"file://s3.gi.org/physicians/guidelines/UlcerBleeding.pdf\">",
"     guideline",
"    </a>",
"    issued by the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. A general approach to patients with UGI bleeding, general treatment of patients with peptic ulcer disease, an overview of the complications of peptic ulcer disease, a detailed discussion of the tools used for endoscopic hemostasis, and detailed discussions of angiographic and surgical management of patients with peptic ulcer disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with upper gastrointestinal (UGI) bleeding starts with assessing hemodynamic stability and determining the need for fluid resuscitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood transfusion. This part of the evaluation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with clinically significant UGI bleeding (ie, signs of active UGI bleeding including hematemesis, melena, or hematochezia, with or without hemodynamic instability or blood transfusion requirement) should be started on an intravenous proton pump inhibitor while undergoing their initial evaluation. Once the patient is stabilized, endoscopy is performed to diagnose high-risk lesions (",
"    <a class=\"graphic graphic_table graphicRef52860 \" href=\"UTD.htm?22/7/22651\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/6\">",
"     6",
"    </a>",
"    ]. Ulcers that are actively bleeding and most nonbleeding ulcers that are at high-risk for recurrent bleeding based upon the presence of stigmata of recent hemorrhage require endoscopic therapy. Ulcers that lack high-risk stigmata can be managed acutely with acid suppression alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64438587\">",
"    <span class=\"h2\">",
"     Stigmata of recent hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain endoscopic findings, known as stigmata of recent hemorrhage, are associated with an increased risk of recurrent bleeding (up to 90 percent depending upon the finding) (",
"    <a class=\"graphic graphic_table graphicRef78607 \" href=\"UTD.htm?22/10/22699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The appearance of ulcers can be described using the Forrest classification [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class Ia &ndash; Spurting hemorrhage (",
"      <a class=\"graphic graphic_picture graphicRef61646 \" href=\"UTD.htm?8/57/9119\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef50116 \" href=\"UTD.htm?39/39/40574\">",
"       movie 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Class Ib &ndash; Oozing hemorrhage",
"     </li>",
"     <li>",
"      Class IIa &ndash; Nonbleeding visible vessel (",
"      <a class=\"graphic graphic_picture graphicRef54960 graphicRef79058 graphicRef61604 \" href=\"UTD.htm?4/61/5082\">",
"       picture 2A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Class IIb &ndash; Adherent clot (",
"      <a class=\"graphic graphic_picture graphicRef76246 \" href=\"UTD.htm?10/24/10628\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Class IIc &ndash; Flat pigmented spot (",
"      <a class=\"graphic graphic_picture graphicRef52497 \" href=\"UTD.htm?40/62/41966\">",
"       picture 4B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Class III &ndash; Clean ulcer base (",
"      <a class=\"graphic graphic_picture graphicRef74032 \" href=\"UTD.htm?16/48/17167\">",
"       picture 4A",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stigmata of recent hemorrhage are present if anything other than a clean ulcer base is seen. However, only patients with active bleeding (spurting or oozing), a nonbleeding visible vessel, or an adherent clot are generally considered to be at high-risk for recurrent bleeding. Most patients with high-risk stigmata require endoscopic therapy to decrease the risk of recurrent bleeding. On the other hand, patients without these high-risk stigmata are considered low-risk and do not require endoscopic therapy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Endoscopic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H97408859\">",
"     'Inpatient versus outpatient management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97408859\">",
"    <span class=\"h1\">",
"     INPATIENT VERSUS OUTPATIENT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalization is required for patients at high-risk for recurrent bleeding, patients with evidence of severe upper gastrointestinal (UGI) bleeding (hemodynamic instability, blood transfusion requirement), and patients at increased risk for complications should bleeding recur (eg, significant coronary artery or cerebrovascular disease, age over 65 years, patients taking antiplatelet or anticoagulant medications). Patients who are otherwise healthy and who are at low risk for recurrent UGI bleeding may be safely allowed to eat and discharged from the hospital on oral antisecretory therapy once the effects of procedural sedation have worn off, provided that the patient is reliable and can promptly get medical care should bleeding recur. (See",
"    <a class=\"local\" href=\"#H64438587\">",
"     'Stigmata of recent hemorrhage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Post-procedure monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to findings at the time of endoscopy, risk stratification scores can help differentiate patients who require hospitalization from those who are appropriate for outpatient management. It is recommended in the International Consensus Recommendations that all patients with upper gastrointestinal bleeding undergo risk stratification using a validated prognostic scale such as the Rockall score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/11/27838?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), Blatchford score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/56/19329?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), or AIMS65 score [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early discharge and return to work can significantly reduce both direct costs (eg, hospitalization cost) and indirect costs (eg, days lost from work) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The safety of early discharge for low-risk patients was demonstrated in a retrospective study with 72 patients with a bleeding duodenal ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/8\">",
"     8",
"    </a>",
"    ]. All of the patients were under the age of 60 years and presented with stable vital signs. On endoscopy, they had no stigmata of recent hemorrhage or only flat spots seen. The mean hospital stay was 1.4 days, and there were no episodes of recurrent bleeding or significant drops in hemoglobin concentration two weeks after discharge. The investigators then performed a prospective study with 75 similar patients and discharged them on the same day of endoscopy. There were no episodes of recurrent bleeding or significant drops in hemoglobin one week after discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57224533\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with bleeding peptic ulcers should receive acid suppressive treatment with a proton pump inhibitor. In general, a high-dose intravenous (IV) proton pump inhibitor (PPI) should be initiated in all patients with suspected clinically significant upper gastrointestinal bleeding prior to endoscopy as part of their initial management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079756#H5079756\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57224540\">",
"    <span class=\"h2\">",
"     Acid suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with PPIs leads to elevation of gastric pH levels, which stabilizes blood clots and improves clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/10-20\">",
"     10-20",
"    </a>",
"    ]. As a result, PPIs are recommended for all patients with peptic ulcer bleeding. Prior to endoscopy, patients are typically started on a continuous infusion of an intravenous PPI. Twice daily dosing of an oral proton pump inhibitor may be a reasonable alternative if intravenous formulations are not available. (See",
"    <a class=\"local\" href=\"#H57226173\">",
"     'High-dose versus non-high-dose PPIs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H57224583\">",
"     'Oral dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most studies have evaluated intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , a formulation that is not available in all countries, including the United States. Although the efficacy of intravenous formulations of other PPIs has not been studied extensively, they are probably acceptable alternatives when given in doses that are known to inhibit gastric acid secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/21\">",
"     21",
"    </a>",
"    ]. The suggested dose of IV omeprazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    is a bolus of 80 mg followed by a continuous infusion at a rate of 8 mg per hour. Pantoprazole and esomeprazole are the only intravenous formulations available in the United States, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    has been removed from the world market.",
"   </p>",
"   <p>",
"    In patients with high-risk stigmata of recent hemorrhage, the IV PPI may be switched to a standard-dose PPI (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg daily) 72 hours after endoscopy, provided there is no evidence of recurrent bleeding. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Treatment of persistent and recurrent bleeding'",
"    </a>",
"    below.) It is unlikely that an IV PPI would be of significant benefit in patients who do not have active bleeding or other high-risk stigmata (such as a visible vessel or adherent clots) because their risk of recurrent bleeding is low. Such patients may be switched to a standard dose oral PPI immediately following endoscopy. The goal of treatment in low-risk patients should be directed at healing the ulcers and eliminating precipitating factors (such as",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    and nonsteroidal antiinflammatory drugs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of H2 receptor antagonists (H2RAs) in bleeding peptic ulcers have produced mixed but generally disappointing results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/12,22-25\">",
"     12,22-25",
"    </a>",
"    ]. A meta-analysis concluded that there was a possible minor benefit with IV H2RAs in bleeding gastric ulcers but no benefit with duodenal ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/24\">",
"     24",
"    </a>",
"    ]. The improved efficacy seen with PPIs may be due to their superior ability to maintain a gastric pH at a level above 6.0.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57224576\">",
"    <span class=\"h3\">",
"     Efficacy of proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 21 randomized trials that compared PPIs with either placebo or an H2RA for bleeding ulcers (with or without endoscopic therapy) found a significant and consistent reduction in the risk of recurrent bleeding (OR 0.46, 95% CI 0.33-0.64) and the need for surgery (OR 0.59, 95% CI 0.46-0.76) with PPIs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/10\">",
"     10",
"    </a>",
"    ]. However, there was no effect on mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An illustrative trial included 240 patients with ulcers that were actively bleeding or had a visible vessel. The patients were randomly assigned to IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      or placebo following endoscopic hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/14\">",
"       14",
"      </a>",
"      ]. Recurrent bleeding was observed significantly less often in patients receiving omeprazole (7 versus 23 percent), a finding that led to early termination of the trial. A separate analysis based upon these data suggested that the addition of IV omeprazole was cost-effective compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second randomized trial (published after the meta-analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/10\">",
"       10",
"      </a>",
"      ]) included 638 patients admitted with upper gastrointestinal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/19\">",
"       19",
"      </a>",
"      ]. Patients were assigned to either IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      or placebo at the time of admission. Patients then underwent endoscopy the following morning. Patients who received omeprazole were less likely than those who received placebo to have endoscopic signs of active bleeding (6 versus 15 percent) or to require endoscopic hemostatic therapy (19 versus 28 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57226173\">",
"    <span class=\"h3\">",
"     High-dose versus non-high-dose PPIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs given for the treatment of bleeding peptic ulcers are often given as high-dose continuous infusions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    80 mg bolus followed by 8 mg per hour). However, studies comparing high-dose with non-high-dose PPIs have failed to show a difference in clinically relevant endpoints. As an example, a trial with 238 patients with actively bleeding ulcers or nonbleeding visible vessels compared high-dose IV PPIs (either omeprazole or pantoprazole given as a continuous infusion) with a lower-dose IV PPI (omeprazole or pantoprazole given as a 40 mg intravenous bolus twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/27\">",
"     27",
"    </a>",
"    ]. There were no differences between those who received high-dose and lower-dose PPIs with regard to recurrent bleeding (8 percent in both groups), need for surgery (1 versus 0.4 percent), mean units of blood transfused (1.7 versus 1.5 units), or mortality (2 percent in both groups). Fewer patients in the high-dose group had a hospital stay of less than five days (37 versus 47 percent).",
"   </p>",
"   <p>",
"    A meta-analysis that included seven randomized trials with 1157 patients who had received endoscopic treatment for a bleeding ulcer compared recurrent bleeding rates, the need for surgical intervention, and mortality between patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    (both given as an 80 mg bolus followed by 8",
"    <span class=\"nowrap\">",
"     mg/h)",
"    </span>",
"    and patients receiving non-high-dose omeprazole or pantoprazole (with oral doses ranging from 80 to 160 mg per day and IV doses ranging from 20 to 80 mg per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/28\">",
"     28",
"    </a>",
"    ]. There were no differences in any of the outcomes between the two groups. However, methodologic concerns regarding the meta-analysis have been raised, including the fact that some studies in the meta-analysis included patients who did not have high-risk stigmata of recent hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H64438587\">",
"     'Stigmata of recent hemorrhage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend that, in addition to appropriate endoscopic management, patients with actively bleeding peptic ulcers or ulcers with high-risk stigmata (such as a visible vessel or adherent clot) receive an IV PPI. While more data are needed to guide the appropriate dosing of PPIs in these patients, we suggest that until such data become available, patients be treated in accordance with the International Consensus Recommendation, which suggests that patients with high-risk stigmata receive an IV bolus of a PPI followed by a continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/3\">",
"     3",
"    </a>",
"    ]. When IV formulations are not available, we suggest twice daily dosing of a high-dose oral PPI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57224583\">",
"    <span class=\"h3\">",
"     Oral dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral dosing of PPIs is less expensive than IV dosing, and some studies suggest it may be an option for the treatment of patients with peptic ulcer bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/32\">",
"     32",
"    </a>",
"    ]. However, oral dosing has not been directly compared with high-dose IV therapy. Currently, where available, IV dosing is considered standard of care. If oral dosing is being considered, a high-dose of an oral PPI should probably be used (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    40 mg twice per day).",
"   </p>",
"   <p>",
"    Studies of oral dosing have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined analysis of five trials evaluating oral dosing (with or without endoscopic therapy) found a significant reduction in the risk of recurrent bleeding and surgery compared with treatment with placebo or an H2RA [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/10\">",
"       10",
"      </a>",
"      ]. However, oral dosing was not compared with high-dose IV dosing.",
"     </li>",
"     <li>",
"      A randomized trial conducted in 110 patients in a setting where therapeutic endoscopy was not available found that high-dose oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      (40 mg twice daily) was associated with a decreased risk of recurrent bleeding compared with placebo in patients who had ulcers with visible vessels or adherent clots who did",
"      <strong>",
"       not",
"      </strong>",
"      undergo endoscopic therapy (11 versus 36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another randomized trial included 160 patients who were at high risk for recurrent bleeding and had been treated with endoscopic injection therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/33\">",
"       33",
"      </a>",
"      ]. The patients who were assigned to receive oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      had a significantly lower rebleeding rate than those who received placebo (12 versus 26 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High doses of PPIs given orally achieve adequate acid suppression more rapidly than standard doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg daily), which may take several days to achieve adequate acid suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, high-dose IV PPIs achieve adequate acid suppression more rapidly than high-dose oral PPIs. A randomized trial comparing intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    (90 mg bolus followed by a 9",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    infusion) with oral lansoprazole (120 mg followed by 30 mg every three hours) in patients with bleeding ulcers found that achievement of an intragastric pH &gt;6 was similar (68 versus 64 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the group that received IV lansoprazole achieved a more rapid increase in pH, reaching a mean pH of 6 approximately one hour sooner than the group that received an oral PPI (after two to three hours compared with three to four hours). Whether such frequent dosing of the oral PPI was necessary to achieve comparable clinical outcomes is unclear, and we suggest that if a high-dose oral PPI is going to be used, that it be given twice daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57224611\">",
"    <span class=\"h2\">",
"     Somatostatin and octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin and its long-acting analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (commonly used in the management of variceal bleeding) have a theoretical benefit in bleeding ulcer disease because they reduce splanchnic blood flow, inhibit gastric acid secretion, and may have gastric cytoprotective effects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A clinical benefit has been described in ulcer bleeding, but because of the effectiveness of endoscopic therapy, its role is generally limited to settings in which endoscopy is unavailable or as a means to help stabilize patients before definitive therapy can be performed.",
"   </p>",
"   <p>",
"    Several studies have described the experience with these agents in patients with acute nonvariceal upper gastrointestinal bleeding. A meta-analysis of these trials suggested that somatostatin was associated with a reduced risk of continued bleeding (relative risk 0.53; 95% CI, 0.43 to 0.63) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk also appeared to be reduced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , although there were fewer studies. Thus, somatostatin or octreotide can be used as adjunctive therapy before endoscopy, or when endoscopy is unsuccessful, contraindicated, or unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/39\">",
"     39",
"    </a>",
"    ]. The doses used in the above studies were variable; a typical dose of somatostatin was 250 mcg given as a bolus followed by an infusion of 250 mcg per hour for three to seven days, while a typical dose of octreotide was 50 to 100 mcg given as a bolus followed by an infusion of 25 mcg per hour for up to three days. Of note, the dose of octreotide used is lower than that used for variceal bleeding (50 mcg bolus followed by an infusion of 50 mcg per hour), so if there is concern prior to the endoscopy that the bleed could be due to varices, the higher dose of octreotide should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of active variceal hemorrhage\", section on 'Somatostatin and its analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H256614307\">",
"    <span class=\"h2\">",
"     Prokinetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously over 20 to 30 minutes may be given 30 to 90 minutes prior to endoscopy to aid with endoscopic visualization. We typically reserve the use of such agents for patients who are likely to have a large amount of blood in their stomach. The use of prokinetic agents to aid with endoscopic visualization is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079922#H5079922\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Prokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic therapy is indicated for the treatment of most ulcers with stigmata of recent hemorrhage that increase the risk of recurrent bleeding. With appropriate treatment, high-risk lesions have recurrent bleeding rates of 5 to 20 percent, depending upon the endoscopic appearance of the ulcer. On the other hand, ulcers with a clean base or a flat pigmented spot are at low risk of recurrent bleeding (3 to 5 percent for clean-based ulcers and 7 to 10 percent for ulcers with a flat spot) and should not be treated endoscopically (",
"    <a class=\"graphic graphic_picture graphicRef74032 graphicRef52497 \" href=\"UTD.htm?4/27/4530\">",
"     picture 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adherent clots that are not easily removed endoscopically (eg, with irrigation or gentle suctioning of the clot away from the ulcer crater to reveal the underlying stigmata) carry a 20 to 30 percent risk of recurrent bleeding. A traditional dictum has been to leave these clots in situ and manage patients medically. More recent experience suggests that removing the clot (eg, using a cold guillotine technique with a polypectomy snare) and then treating the underlying ulcer stigmata can significantly reduce the risk of recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, meta-analyses have reached variable results. One meta-analysis of six studies with a total of 240 patients concluded that endoscopic therapy was associated with a significantly lower rate of recurrent hemorrhage in patients with bleeding peptic ulcers and adherent clots (8 versus 25 percent with medical therapy alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/42\">",
"     42",
"    </a>",
"    ]. On the other hand, a later meta-analysis found no clear evidence supporting specific endoscopic interventions in patients with an adherent clot [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the significant risk of recurrent bleeding in patients with adherent clots, we suggest that gentle attempts be made to remove the clot so that endoscopic treatment can be applied if needed, provided the ulcer is in a location that is amenable to endoscopic therapy should bleeding start, that additional surgical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interventional radiology support is available, and that the endoscopist performing the procedure is comfortable with the techniques involved with clot removal. If these conditions are not met and the patient is not actively bleeding, high dose IV PPI treatment alone is a reasonable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97409140\">",
"    <span class=\"h2\">",
"     Choice of endoscopic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several types of endoscopic treatment for bleeding peptic ulcers have been described, including injection therapy, thermal coagulation, hemostatic clips, fibrin sealant (or glue), argon plasma coagulation, and combination therapy (typically injection of epinephrine combined with another treatment modality), relatively few prospective comparative trials have been performed. Currently, most patients are treated with either thermal coagulation therapy or hemostatic clips, with or without the addition of injection therapy. This approach is based upon results from meta-analyses of randomized trials comparing different forms of treatment to control bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One analysis included 74 randomized trials that compared endoscopic methods to control bleeding in patients considered to be at high risk for recurrent ulcer bleeding (ie, those with active bleeding, a nonbleeding visible vessel, or an adherent clot) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/43\">",
"     43",
"    </a>",
"    ]. The primary endpoint was persistent or recurrent bleeding. The following were the major conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with epinephrine monotherapy, the risk of further bleeding was significantly lower with other monotherapies, such as thermal coagulation (relative risk [RR] 0.6) or epinephrine followed by another modality (RR 0.3).",
"     </li>",
"     <li>",
"      Hemoclips were more effective than epinephrine alone for preventing recurrent bleeding (RR 0.2) but were not different than other endoscopic therapies.",
"     </li>",
"     <li>",
"      The efficacy of endoscopic therapies for adherent clots was uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between hemoclips and thermal therapy will often depend upon factors such as the location of the ulcer and the preference of the endoscopist. Detailed discussions of the endoscopic techniques used for hemostasis are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407607\">",
"    <span class=\"h2\">",
"     Standard approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard approaches to treatment include thermal coagulation and hemoclip placement. In addition, both of these modalities can be combined with injection therapy, an approach known as combination therapy (",
"    <a class=\"graphic graphic_picture graphicRef56986 \" href=\"UTD.htm?13/4/13383\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407324\">",
"    <span class=\"h3\">",
"     Injection therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection therapy should be used in conjunction with other forms of therapy, such as thermal coagulation or hemoclip placement. Injection therapy should not be used as monotherapy because it is associated with higher rates of recurrent bleeding than treatment with thermal coagulation, hemoclip placement, or combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/43,46\">",
"     43,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injection therapy with dilute epinephrine results in local tamponade and vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The technique is inexpensive and effective for temporary hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]. Epinephrine diluted with saline to 1:10,000 to 1:20,000 is injected in 0.5 to 2.0 mL aliquots in four quadrants within 3 mm of the bleeding site. In patients who are at increased risk of having an adverse event with epinephrine injection, such as those with significant cardiac disease or those with lesions close to the esophagogastric junction (epinephrine injected into this area may enter the systemic circulation without a first pass through the liver), a dilution of 1:100,000 can be used.",
"   </p>",
"   <p>",
"    A potential advantage of epinephrine injection is that it is easy to administer, can help slow or stop bleeding, and can reduce bleeding after attempts at mechanical hemostasis. During active bleeding, it can also produce a cleaner field, permitting targeted treatment of the bleeding site. Addition of a sclerosant (eg, ethanolamine) confers no advantage over injection with epinephrine alone and may cause tissue damage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injection of saline also causes local tamponade, which can be effective in achieving temporary hemostasis. However, as was seen in studies comparing epinephrine monotherapy with other therapeutic modalities, saline injection alone is associated with higher recurrent bleeding rates compared with other standard therapies. In a randomized trial with 100 patients with high-risk bleeding ulcers, recurrent bleeding occurred more often with saline monotherapy compared with thermal coagulation (29 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Thermal coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermal coagulation with contact probes achieves acute hemostasis and prevents recurrent bleeding by coaptive coagulation of the underlying artery in the ulcer base (",
"    <a class=\"graphic graphic_picture graphicRef79058 \" href=\"UTD.htm?27/62/28643\">",
"     picture 2B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70660 \" href=\"UTD.htm?31/15/31986\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/49\">",
"     49",
"    </a>",
"    ]. Coaptive coagulation involves applying pressure to the vessel with the probe to compress it while coagulation is performed. This results in sealing (coaptation) of vessel. A detailed discussion of thermal coagulation is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=see_link\">",
"     \"Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An alternate form of thermal coagulation uses argon plasma coagulation (APC). This approach has a theoretical disadvantage for the treatment of bleeding ulcers since it is not coaptive. Nevertheless, at least two randomized trials suggested that APC can be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407465\">",
"    <span class=\"h3\">",
"     Hemoclips",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endoscopic application of hemoclips is an alternative to thermal coagulation. Once applied, the clips achieve hemostasis in a manner similar to surgical ligation. Placement of a hemoclip can be of value even if an ulcer is not amenable to endoscopic therapy, since it may serve as a radiopaque marker for subsequent interventional angiographic or surgical intervention. The use of hemoclips in the treatment of upper gastrointestinal bleeding is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407657\">",
"    <span class=\"h2\">",
"     Alternative approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternatives to standard endoscopic therapy that are being studied include the use of tissue adhesives and agents that promote hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fibrin sealant",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach involves the use of endoscopically injected fibrin sealant to achieve initial hemostasis and decrease the rate of recurrent bleeding. An unblinded, multicenter, randomized trial of 854 patients with actively bleeding gastroduodenal ulcers compared the safety and efficacy of a single application of fibrin sealant, daily repeated doses of fibrin sealant until the visible vessel disappeared, or a single application of the sclerosant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     polidocanol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/55\">",
"     55",
"    </a>",
"    ]. While the safety profiles of all three treatment strategies were similar, the patients who received multiple applications of fibrin sealant had significantly less recurrent bleeding than the polidocanol group (15 versus 23 percent) and had fewer acute treatment failures (8 versus 13 percent). However, the resources necessary to perform repeated endoscopies are not inconsequential, and the precise role for fibrin sealant in this setting remains to be defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"     \"Fibrin sealant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407830\">",
"    <span class=\"h3\">",
"     Hemostatic nanopowder",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nanopowder that promotes hemostasis (Hemospray, Cook Medical Inc, Winston-Salem, NC) has been developed that becomes cohesive and adhesive when it comes into contact with moisture, forming a stable mechanical barrier at the site of bleeding. The powder is delivered through a catheter and sprayed onto the bleeding site under endoscopic guidance, without the need for direct tissue contact. Potential advantages of this hemostatic approach are that it is easy to apply, does not require an en face view of the ulcer, and does not require direct tissue contact.",
"   </p>",
"   <p>",
"    In a pilot study, 20 patients with oozing peptic ulcers were treated with the powder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/56\">",
"     56",
"    </a>",
"    ]. Acute hemostasis was achieved in 19 patients (95 percent). Bleeding recurred in two patients (10 percent) within 72 hours (defined by a drop in hemoglobin), but no active bleeding was identified at follow-up endoscopy. There were no serious treatment-related adverse events. This treatment modality is currently being studied in prospective trials and is not available in the United States, although it is available in Canada and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407838\">",
"    <span class=\"h3\">",
"     Cyanoacrylate injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanoacrylate is a tissue adhesive that, when introduced into an aqueous environment, immediately polymerizes into a firm clot. It is most often used in the treatment of bleeding gastric varices. It has also been used successfully for the treatment of refractory peptic ulcer bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. However, its use has also been associated with arterial and portal venous embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/58,59,61,62\">",
"     58,59,61,62",
"    </a>",
"    ]. While used outside of the United States (primarily for variceal bleeding), there is limited availability of cyanoacrylate within the US, and it is only used in a few centers.",
"   </p>",
"   <p>",
"    In a randomized trial, 126 patients with peptic ulcers with active bleeding or a nonbleeding visible vessel were assigned to either treatment with hypertonic saline-epinephrine injection or injection with cyanoacrylate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/61\">",
"     61",
"    </a>",
"    ]. There were no differences between the epinephrine and cyanoacrylate groups with regard to permanent hemostasis (81 and 90 percent, respectively), emergency surgery (12 and 5 percent, respectively), or in-hospital mortality due to bleeding (0 percent for both groups). In the subgroup of patients with active bleeding at the time of endoscopy, treatment with epinephrine was associated with a higher recurrent bleeding rate compared with cyanoacrylate treatment (42 versus 14 percent). However, epinephrine monotherapy is not the standard of care, and it is not known how cyanoacrylate injection would compare with thermal coagulation, hemoclip therapy, or combination therapy. In addition, in this trial there were two cases of cyanoacrylate-related arterial embolization with infarction, one of which was fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the unclear benefit of cyanoacrylate injection combined with its serious side effects, we do not recommend it for the treatment of bleeding gastric ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6550756\">",
"    <span class=\"h2\">",
"     Second-look endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-look endoscopy refers to the practice of performing a planned follow-up endoscopy, generally within 24 hours of the initial endoscopy. If there is active bleeding or a nonbleeding visible vessel, endoscopic therapy is performed. Data are conflicting regarding the benefits of second-look endoscopy, and in general, guidelines and reviews do not recommend it [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/3,63,64\">",
"     3,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One problem with the available studies is that many were performed without optimal hemostatic approaches (eg, treatment with epinephrine monotherapy rather than combination therapy) and did not include the use of proton pump inhibitors. A meta-analysis that included five randomized trials with 998 patients found that second-look endoscopy with thermal coagulation was associated with a decreased risk of rebleeding (relative risk [RR] 0.29; 95% confidence interval [CI] 0.11-0.73), but second-look endoscopy with injection therapy was not (RR 0.85; 95% CI 0.63-1.14). [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, second-look endoscopy was not associated with a decreased risk of surgery or mortality.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis with eight randomized trials with 938 patients found that compared with standard medical care, routine second-look endoscopy was associated with a decreased risk of rebleeding (odds ratio [OR] 0.55; 95% CI 0.37-0.81) and surgery (OR 0.43; 95% CI 0.19-0.96), but not mortality (OR 0.65; 95% CI 0.26-1.62) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/66\">",
"     66",
"    </a>",
"    ]. However, only one of the included studies treated patients with a high-dose proton pump inhibitor, and three of the studies did not use cautery or hemoclipping as part of the endoscopic treatment. Finally, when two trials that included patients at high risk for rebleeding were removed, the benefit with second-look endoscopy was no longer seen.",
"   </p>",
"   <p>",
"    The 2010 International Consensus Recommendations for the management of patients with nonvariceal upper gastrointestinal bleeding do not recommend routine use of second-look endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the guidelines also suggest that patients at particularly high risk for recurrent bleeding may benefit from second-look endoscopy.",
"   </p>",
"   <p>",
"    Situations that might warrant a second-look endoscopy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If visualization during the initial endoscopy was limited by blood or debris",
"     </li>",
"     <li>",
"      If there is concern on the part of the endoscopist that the prior endoscopic therapy was sub-optimal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, repeat endoscopy is indicated if there is recurrent bleeding in order to exclude previously missed lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to retreat the bleeding ulcer. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Treatment of persistent and recurrent bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97406903\">",
"    <span class=\"h2\">",
"     Treatment related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications can arise prior to, during, or after emergency endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/67\">",
"     67",
"    </a>",
"    ]. Complications that may occur before endoscopy include aspiration (especially in a sedated, combative, or encephalopathic patient), hypoventilation (related to oversedation), or hypotension (due to inadequate volume replacement or transfusions, in addition to sedation with opiates). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=see_link&amp;anchor=H67011650#H67011650\">",
"     \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complications of endoscopic therapy include perforation and precipitation (or worsening) of bleeding. In addition, epinephrine can cause tachycardia and arrhythmias. Aggressive initial treatment or repeated applications of thermal or injection therapy may improve hemostasis, but also increase the risk of treatment-induced complications. Thus, predetermined limits (volume of injection solution, total treatment pulses, and total energy delivered) should be set and not exceeded for each technique, in order to minimize the risk of complications. We usually do not exceed 20 mL of epinephrine (1:10,000 dilution) injection or more than five pulses of thermal coagulation. In addition, in patients at increased risk for cardiac complications from epinephrine, one option is to further dilute the epinephrine to 1:100,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT OF PERSISTENT AND RECURRENT BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of bleeding ulcers can be controlled endoscopically, some patients have persistent or recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Persistent bleeding refers to active bleeding that does not stop despite endoscopic therapy or bleeding that develops during endoscopic therapy of a nonbleeding lesion that cannot be controlled endoscopically. Recurrent bleeding refers to bleeding that occurs following spontaneous hemostasis or after successful endoscopic hemostasis.",
"   </p>",
"   <p>",
"    The following criteria have been proposed for defining recurrent bleeding in studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematemesis or bloody nasogastric aspirate more than 6 hours after endoscopy",
"     </li>",
"     <li>",
"      Melena after normalization of stool color",
"     </li>",
"     <li>",
"      Hematochezia after normalization of stool color or after melena",
"     </li>",
"     <li>",
"      Development of tachycardia (heart rate &ge;110 beats per minute) or hypotension (systolic blood pressure &le;90&thinsp;mmHg) after at least one hour of hemodynamic stability (ie, no tachycardia or hypotension) in the absence of an alternative explanation for hemodynamic instability, such as sepsis, cardiogenic shock, or medications (of note, many endoscopists, ourselves included, consider tachycardia to be present if the heart rate is greater than 100 beats per minute)",
"     </li>",
"     <li>",
"      Hemoglobin drop of 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or more after two consecutive stable hemoglobin values (less than a 0.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease) obtained at least three hours apart",
"     </li>",
"     <li>",
"      Tachycardia or hypotension that does not resolve within eight hours after index endoscopy despite appropriate resuscitation (in the absence of an alternative explanation), associated with persistent melena or hematochezia",
"     </li>",
"     <li>",
"      Persistently dropping hemoglobin of more than 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in 24 hours, associated with persistent melena or hematochezia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with one episode of recurrent bleeding following initially successful endoscopic therapy are typically treated with a second attempt at endoscopic therapy. Therapy may consist of the same therapy initially used or a different endoscopic modality (eg, if thermocoagulation therapy was used initially it may either be repeated or treatment with a hemostatic clip employed). Surgery or angiography-guided intervention is indicated for patients who fail endoscopic therapy (persistent bleeding or recurrent bleeding after two therapeutic endoscopies).",
"   </p>",
"   <p>",
"    This approach was supported by a randomized trial that included 92 patients with recurrent bleeding after endoscopic therapy who were randomly assigned to repeat endoscopic therapy or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/71\">",
"     71",
"    </a>",
"    ]. Long-term control of bleeding was achieved in 35 of 48 patients (73 percent) treated with repeated endoscopic therapy. Salvage surgery was performed in the 13 patients who failed endoscopic therapy (11 because of continued bleeding and two because of perforation resulting from thermocoagulation). Mortality was similar between the two groups, though complications were less frequent in the endoscopy group (15 versus 36 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407782\">",
"    <span class=\"h2\">",
"     Risk factors for persistent or recurrent bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors associated with persistent or recurrent bleeding include, ulcer location, the patient's presentation, the appearance of the ulcer at the time of endoscopy, size of the ulcer, and presence of comorbid illnesses.",
"   </p>",
"   <p>",
"    In one report, gastric ulcers along the lesser curvature and duodenal ulcers along the posterior wall of the duodenal bulb were at greater risk for severe or recurrent bleeding compared with ulcers in other locations because of their proximity to large underlying arteries (left gastric and posterior gastroduodenal arteries, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, patients who presented with active hemorrhage, shock, and the lowest hemoglobin concentrations did less well than those without these risk factors. Factors that did",
"    <strong>",
"     not",
"    </strong>",
"    predict the outcome of endoscopic therapy were a history of nonsteroidal anti-inflammatory drug or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use, coagulopathy, previous peptic ulceration, and concomitant cardiorespiratory disease. In another report, severe bleeding, active bleeding, fresh blood in the stomach, and large ulcers (2 cm in diameter or larger) were independent risk factors for therapeutic failure after injection of epinephrine plus heater probe treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/69\">",
"     69",
"    </a>",
"    ]. Large ulcers tend to have larger blood vessels (&gt;2 to 3 mm), and ulcers in the posterior duodenal bulb also may have a large vessel (gastroduodenal artery). These large vessels may be difficult or not possible to control with endoscopic therapies, and we advise the use of endoscopic combination therapies as well as a low-threshold to advance to other therapies including angiography and surgery.",
"   </p>",
"   <p>",
"    A meta-analysis of 10 studies found that predictors of recurrent bleeding included active bleeding at endoscopy, large ulcers (&gt;1 to 2 cm), posterior duodenal ulcers, and gastric ulcers on the lesser curvature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    End-stage renal disease may also increase the risk of recurrent bleeding. A case-control study of 150 patients found that patients with end-stage renal disease requiring dialysis were more likely to experience recurrent bleeding than were patients with chronic kidney disease who were not on dialysis (OR 3.8) or normal controls (OR 3.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, surgery was required for patients who failed endoscopic therapy, though depending upon local resources and expertise, many patients now undergo an attempt at interventional angiography prior to surgery. Surgical treatments for peptic ulcer disease include oversewing of the artery with truncal vagotomy and pyloroplasty, antrectomy with gastrojejunostomy (Billroth II procedure), and highly selective vagotomy. Emergency surgery for bleeding peptic ulcer disease involves oversewing of the ulcer (to ligate the bleeding artery) plus truncal vagotomy (to decrease acid secretion) and pyloroplasty (for gastric drainage). More time consuming procedures, such as highly selective vagotomy, can be performed either at standard laparotomy or laparoscopically for non-emergency ulcer surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=see_link&amp;anchor=H493274237#H493274237\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Bleeding ulcers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link\">",
"     \"Role of surgery in the management of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to failure of endoscopic therapy, other indications for surgery for peptic ulcer hemorrhage include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability despite vigorous resuscitation (more than a three unit transfusion)",
"     </li>",
"     <li>",
"      Shock associated with recurrent hemorrhage",
"     </li>",
"     <li>",
"      Perforation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary or relative indications include rare blood type, difficult crossmatch, refusal of transfusion, shock on presentation, advanced age, severe comorbid disease, and chronic gastric ulcer as the origin of hemorrhage. In addition, surgery may be appropriate for elderly patients who are unlikely to tolerate prolonged attempts at resuscitation, large volume transfusions, or periods of hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If performed emergently, surgery is associated with high mortality rates (up to 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/76\">",
"     76",
"    </a>",
"    ]. On the other hand, early elective surgery is associated with a much lower mortality rate (0 to 7 percent). Recurrent bleeding rates following surgery vary from 3 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97407746\">",
"    <span class=\"h2\">",
"     Interventional angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography with transarterial embolization (TAE) for persistent or recurrent peptic ulcer bleeding is a less invasive alternative to surgery. Initial success rates for patients with acute peptic ulcer bleeding are between 52 and 98 percent, with recurrent bleeding rates of 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for interventional angiography for acute nonvariceal upper gastrointestinal bleeding have been suggested in a consensus statement from the American College of Radiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/15/24826/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopy is the best initial diagnostic and therapeutic procedure",
"     </li>",
"     <li>",
"      Surgery and transcatheter",
"      <span class=\"nowrap\">",
"       arteriography/intervention",
"      </span>",
"      are equally effective following failed therapeutic endoscopy, but transcatheter",
"      <span class=\"nowrap\">",
"       arteriography/intervention",
"      </span>",
"      should be considered particularly in patients at high risk for surgery",
"     </li>",
"     <li>",
"      Transcatheter",
"      <span class=\"nowrap\">",
"       arteriography/intervention",
"      </span>",
"      is less likely to be successful in patients with impaired coagulation",
"     </li>",
"     <li>",
"      Transcatheter",
"      <span class=\"nowrap\">",
"       arteriography/intervention",
"      </span>",
"      is the best technique for treatment of bleeding into the biliary tree or pancreatic duct",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TAE has been compared with surgical therapy for patients with peptic ulcer bleeding that could not be controlled endoscopically. In a study of 3271 patients with peptic ulcer bleeding, 88 patients (2.7 percent) failed to have their bleeding controlled endoscopically. Thirty-two patients of the 88 patients underwent angiography and 56 underwent surgery. TAE was attempted in 26 patients and was successful in 23 of 26 patients (89 percent). Bleeding recurred in 11 of 32 patients in the angiography group (34 percent). Of the 56 patients who underwent surgery, recurrent bleeding occurred in 7 (13 percent). However, while the recurrent bleeding rate was lower in patients treated with surgery, more complications were seen in the surgery group (68 versus 41 percent). The groups were similar with regard to 30-day mortality, length of hospital stay, and need for transfusion.",
"   </p>",
"   <p>",
"    Given the less invasive nature of angiography, we suggest that patients who have failed endoscopic therapy first undergo attempted angiography with TAE, and that surgery be reserved for those who fail angiographic therapy. However, surgery is a reasonable alternative if an interventional radiologist with expertise in TAE is not available, if the lesion is deemed unlikely to respond to angiographic therapy or if the patient has underlying conditions that may complicate the ability to perform angiography or TAE (eg, renal insufficiency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64438220\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with bleeding peptic ulcers need to be evaluated for factors that predispose to ulcer formation (eg,",
"    <em>",
"     H. pylori",
"    </em>",
"    ) and treated as appropriate. This issue and issues related to maintenance proton pump inhibitor",
"    <span class=\"nowrap\">",
"     use/discontinuation",
"    </span>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=see_link\">",
"     \"Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial evaluation of the patient with upper gastrointestinal (UGI) bleeding involves an assessment of hemodynamic stability and the necessity for fluid resuscitation (",
"      <a class=\"graphic graphic_table graphicRef52860 \" href=\"UTD.htm?22/7/22651\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend endoscopy within 24 hours of presentation for the diagnosis and treatment of active UGI bleeding and for the prevention of recurrent bleeding rather than waiting more than 24 hours (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The majority of patients with UGI bleeding due to peptic ulcer disease will stop bleeding spontaneously, and most will not rebleed during hospitalization. However, a subgroup of patients is at high risk for recurrent hemorrhage. The major endoscopic predictors of persistent or recurrent bleeding include active bleeding at endoscopy, a nonbleeding visible vessel, and an adherent clot (",
"      <a class=\"graphic graphic_table graphicRef78607 \" href=\"UTD.htm?22/10/22699\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H64438587\">",
"       'Stigmata of recent hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with actively bleeding peptic ulcers or ulcers with high-risk stigmata (such as a visible vessel or adherent clot) receive an intravenous proton pump inhibitor (PPI) rather than no acid suppression or an H2 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H57224540\">",
"       'Acid suppression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079756#H5079756\">",
"       \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Acid suppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"       Pantoprazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"       esomeprazole",
"      </a>",
"      are the only intravenous PPI formulations available in the United States. The suggested dose of intravenous pantoprazole, esomeprazole, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      (where available) is 80 mg bolus followed by an 8 mg per hour infusion. (See",
"      <a class=\"local\" href=\"#H57224540\">",
"       'Acid suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that an oral PPI be given when intravenous formulations are not available (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). When used for acute GI bleeding, oral PPIs should be given twice daily at high doses. (See",
"      <a class=\"local\" href=\"#H57224540\">",
"       'Acid suppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that otherwise healthy patients without severe bleeding or high-risk stigmata be discharged following endoscopy on a standard-dose proton pump inhibitor rather than being admitted to the hospital for observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such patients are at low risk for recurrent bleeding. (See",
"      <a class=\"local\" href=\"#H97408859\">",
"       'Inpatient versus outpatient management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with active bleeding (oozing or spurting) or a visible vessel receive endoscopic therapy and acid suppressive therapy rather than acid suppressive therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Endoscopic therapy decreases the risk of recurrent bleeding in patients with these high-risk stigmata. Patients may be treated with thermal coagulation or hemoclips (with or without epinephrine injection) but should not be treated with epinephrine monotherapy due to an increased risk of recurrent bleeding. (See",
"      <a class=\"local\" href=\"#H64438587\">",
"       'Stigmata of recent hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Endoscopic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Whether to treat patients with adherent clots will depend upon the location of the ulcer, the availability of surgical or interventional radiologic backup should bleeding start, and the experience of the endoscopist. Our approach is to make gentle attempts to remove the clot so that endoscopic treatment can be applied if needed, provided the ulcer is in a location that is amenable to endoscopic therapy should bleeding start.",
"     </li>",
"     <li>",
"      Patients with active bleeding, a visible vessel, or an adherent clot should continue to receive an IV PPI continuous infusion for 72 hours following endoscopy. If there are no signs of recurrent bleeding, the patient may then be switched to a standard-dose oral PPI.",
"     </li>",
"     <li>",
"      We suggest that most patients who fail endoscopic therapy first undergo attempted transarterial angiographic embolization (TAE) rather than surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest angiography rather than surgery because it is less invasive and because surgery is still an option in patients who fail angiographic therapy. However, surgery is a reasonable alternative if an interventional radiologist with expertise in TAE is not available, if the lesion is deemed unlikely to respond to angiographic therapy, or if the patient has underlying conditions that may complicate the ability to perform angiography or TAE (eg, renal insufficiency). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment of persistent and recurrent bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with bleeding peptic ulcers need to be evaluated for factors that predispose to ulcer formation (eg,",
"      <em>",
"       H. pylori",
"      </em>",
"      ) and treated as appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=see_link\">",
"       \"Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/1\">",
"      Katschinski B, Logan R, Davies J, et al. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994; 39:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/2\">",
"      Barkun A, Bardou M, Marshall JK, Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/3\">",
"      Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010; 152:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/4\">",
"      Hwang JH, Fisher DA, Ben-Menachem T, et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc 2012; 75:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/5\">",
"      Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/6\">",
"      Longstreth GF, Feitelberg SP. Hospital care of acute nonvariceal upper gastrointestinal bleeding: 1991 versus 1981. J Clin Gastroenterol 1994; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/7\">",
"      Forrest JA, Finlayson ND, Shearman DJ. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/8\">",
"      Lai KC, Hui WM, Wong BC, et al. A retrospective and prospective study on the safety of discharging selected patients with duodenal ulcer bleeding on the same day as endoscopy. Gastrointest Endosc 1997; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/9\">",
"      Longstreth GF, Feitelberg SP. Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage. Lancet 1995; 345:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/10\">",
"      Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/11\">",
"      Aoki T. Intravenous administration of lansoprazole: a preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding. Aliment Pharmacol Ther 1995; 9 Suppl 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/12\">",
"      Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/13\">",
"      Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/14\">",
"      Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/15\">",
"      Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 1997; 32:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/16\">",
"      Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/17\">",
"      Gisbert JP, Gonz&aacute;lez L, Calvet X, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/18\">",
"      Sung JJ, Chan FK, Lau JY, et al. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. Ann Intern Med 2003; 139:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/19\">",
"      Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007; 356:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/20\">",
"      Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/21\">",
"      Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009; 150:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/22\">",
"      Collins R, Langman M. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985; 313:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/23\">",
"      Walt RP, Cottrell J, Mann SG, et al. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/24\">",
"      Levine JE, Leontiadis GI, Sharma VK, Howden CW. Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/25\">",
"      van Rensburg C, Barkun AN, Racz I, et al. Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial. Aliment Pharmacol Ther 2009; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/26\">",
"      Lee KK, You JH, Wong IC, et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc 2003; 57:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/27\">",
"      Andriulli A, Loperfido S, Focareta R, et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol 2008; 103:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/28\">",
"      Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010; 170:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/29\">",
"      Leontiadis GI, Howden CW. Proton pump inhibitor dose for ulcer bleeding: is less really more? Arch Intern Med 2010; 170:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/30\">",
"      Calvet X, Barkun A, Bardou M, et al. High-dose vs non-high-dose PPIs after endoscopic treatment in patients with bleeding peptic ulcer: current evidence is insufficient to claim equivalence. Arch Intern Med 2010; 170:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/31\">",
"      Lin HJ. High or low doses of PPIs for patients with peptic ulcer bleeding? Arch Intern Med 2010; 170:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/32\">",
"      Spiegel BM, Dulai GS, Lim BS, et al. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006; 4:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/33\">",
"      Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/34\">",
"      Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23 Suppl 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/35\">",
"      Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 2008; 134:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/36\">",
"      Bloom SR, Mortimer CH, Thorner MO, et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974; 2:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/37\">",
"      Johansson C, Aly A. Stimulation of gastric mucus output by somatostatin in man. Eur J Clin Invest 1982; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/38\">",
"      Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Ann Intern Med 1997; 127:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/39\">",
"      Choudari CP, Rajgopal C, Elton RA, Palmer KR. Failures of endoscopic therapy for bleeding peptic ulcer: an analysis of risk factors. Am J Gastroenterol 1994; 89:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/40\">",
"      Jensen DM, Kovacs TO, Jutabha R, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002; 123:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/41\">",
"      Bleau BL, Gostout CJ, Sherman KE, et al. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 2002; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/42\">",
"      Kahi CJ, Jensen DM, Sung JJ, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005; 129:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/43\">",
"      Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/44\">",
"      Marmo R, Rotondano G, Piscopo R, et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. Am J Gastroenterol 2007; 102:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/45\">",
"      Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injection and thermo-coagulation in the treatment of non-variceal upper gastrointestinal bleeding: a meta-analysis. Gut 2007; 56:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/46\">",
"      Calvet X, Vergara M, Brullet E, et al. Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers. Gastroenterology 2004; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/47\">",
"      Lai KH, Peng SN, Guo WS, et al. Endoscopic injection for the treatment of bleeding ulcers: local tamponade or drug effect? Endoscopy 1994; 26:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/48\">",
"      Pinkas H, McAllister E, Norman J, et al. Prolonged evaluation of epinephrine and normal saline solution injections in an acute ulcer model with a single bleeding artery. Gastrointest Endosc 1995; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/49\">",
"      Llach J, Bordas JM, Salmer&oacute;n JM, et al. A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. Gastrointest Endosc 1996; 43:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/50\">",
"      M&auml;kel&auml; JT, Kiviniemi H, Laitinen ST. Randomized trial of endoscopic injection sclerosis with ethanolamine oleate and ethanol for bleeding peptic ulcer. Scand J Gastroenterol 1996; 31:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/51\">",
"      Choudari CP, Palmer KR. Endoscopic injection therapy for bleeding peptic ulcer; a comparison of adrenaline alone with adrenaline plus ethanolamine oleate. Gut 1994; 35:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/52\">",
"      Kubba AK, Palmer KR. Role of endoscopic injection therapy in the treatment of bleeding peptic ulcer. Br J Surg 1996; 83:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/53\">",
"      Chung SC, Leong HT, Chan AC, et al. Epinephrine or epinephrine plus alcohol for injection of bleeding ulcers: a prospective randomized trial. Gastrointest Endosc 1996; 43:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/54\">",
"      Laine L, Estrada R. Randomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: is local tamponade enough? Gastrointest Endosc 2002; 55:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/55\">",
"      Rutgeerts P, Rauws E, Wara P, et al. Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer. Lancet 1997; 350:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/56\">",
"      Sung JJ, Luo D, Wu JC, et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/57\">",
"      Kurokohchi K, Maeta T, Ohgi T, et al. Successful treatment of a giant exposed blood vessel in a gastric ulcer by endoscopic sclerotherapy with N-butyl-2-cyanoacrylate. Endoscopy 2007; 39 Suppl 1:E250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/58\">",
"      Fan CS, Soon MS. Portal vein embolization as a complication of Histoacryl injection for a bleeding giant gastric ulcer. Endoscopy 2007; 39 Suppl 1:E110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/59\">",
"      Lee GH, Kim JH, Lee KJ, et al. Life-threatening intraabdominal arterial embolization after histoacryl injection for bleeding gastric ulcer. Endoscopy 2000; 32:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/60\">",
"      Repici A, Ferrari A, De Angelis C, et al. Adrenaline plus cyanoacrylate injection for treatment of bleeding peptic ulcers after failure of conventional endoscopic haemostasis. Dig Liver Dis 2002; 34:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/61\">",
"      Lee KJ, Kim JH, Hahm KB, et al. Randomized trial of N-butyl-2-cyanoacrylate compared with injection of hypertonic saline-epinephrine in the endoscopic treatment of bleeding peptic ulcers. Endoscopy 2000; 32:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/62\">",
"      Kobilica N, Flis V, Sojar V. Major complication after Histoacryl injection for endoscopic treatment of bleeding peptic ulcer. Endoscopy 2012; 44 Suppl 2 UCTN:E204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/63\">",
"      Chiu PW, Sung JJ. High risk ulcer bleeding: when is second-look endoscopy recommended? Clin Gastroenterol Hepatol 2010; 8:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/64\">",
"      Adler DG, Leighton JA, Davila RE, et al. ASGE guideline: The role of endoscopy in acute non-variceal upper-GI hemorrhage. Gastrointest Endosc 2004; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/65\">",
"      Tsoi KK, Chan HC, Chiu PW, et al. Second-look endoscopy with thermal coagulation or injections for peptic ulcer bleeding: a meta-analysis. J Gastroenterol Hepatol 2010; 25:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/66\">",
"      El Ouali S, Barkun AN, Wyse J, et al. Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointest Endosc 2012; 76:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/67\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Complications of upper GI endoscopy. Gastrointest Endosc 2002; 55:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/68\">",
"      Bulut OB, Rasmussen C, Fischer A. Acute surgical treatment of complicated peptic ulcers with special reference to the elderly. World J Surg 1996; 20:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/69\">",
"      Wong SK, Yu LM, Lau JY, et al. Prediction of therapeutic failure after adrenaline injection plus heater probe treatment in patients with bleeding peptic ulcer. Gut 2002; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/70\">",
"      Laine L, Spiegel B, Rostom A, et al. Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol 2010; 105:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/71\">",
"      Lau JY, Sung JJ, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/72\">",
"      Elmunzer BJ, Young SD, Inadomi JM, et al. Systematic review of the predictors of recurrent hemorrhage after endoscopic hemostatic therapy for bleeding peptic ulcers. Am J Gastroenterol 2008; 103:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/73\">",
"      Cheung J, Yu A, LaBossiere J, et al. Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. Gastrointest Endosc 2010; 71:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/74\">",
"      Jensen DM, Cheng S, Kovacs TO, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 1994; 330:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/75\">",
"      Potvin M, Gagner M, Pomp A. Laparoscopic transgastric suturing for bleeding peptic ulcers. Surg Endosc 1996; 10:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/76\">",
"      Abe N, Takeuchi H, Yanagida O, et al. Surgical indications and procedures for bleeding peptic ulcer. Dig Endosc 2010; 22 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/77\">",
"      Ripoll C, Ba&ntilde;ares R, Beceiro I, et al. Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol 2004; 15:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/78\">",
"      Gralnek IM. Will surgery be a thing of the past in peptic ulcer bleeding? Gastrointest Endosc 2011; 73:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/15/24826/abstract/79\">",
"      Millward SF. ACR Appropriateness Criteria on treatment of acute nonvariceal gastrointestinal tract bleeding. J Am Coll Radiol 2008; 5:550.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2573 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24826=[""].join("\n");
var outline_f24_15_24826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64438587\">",
"      Stigmata of recent hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97408859\">",
"      INPATIENT VERSUS OUTPATIENT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57224533\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57224540\">",
"      Acid suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57224576\">",
"      - Efficacy of proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57226173\">",
"      - High-dose versus non-high-dose PPIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57224583\">",
"      - Oral dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57224611\">",
"      Somatostatin and octreotide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H256614307\">",
"      Prokinetic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENDOSCOPIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97409140\">",
"      Choice of endoscopic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97407607\">",
"      Standard approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97407324\">",
"      - Injection therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Thermal coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97407465\">",
"      - Hemoclips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97407657\">",
"      Alternative approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97407830\">",
"      - Hemostatic nanopowder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97407838\">",
"      - Cyanoacrylate injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6550756\">",
"      Second-look endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97406903\">",
"      Treatment related complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT OF PERSISTENT AND RECURRENT BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97407782\">",
"      Risk factors for persistent or recurrent bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97407746\">",
"      Interventional angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64438220\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2573|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/57/9119\" title=\"picture 1\">",
"      Actively bleeding GU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/44/34500\" title=\"picture 2A\">",
"      Duodenal ulcer with visible vessel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/62/28643\" title=\"picture 2B\">",
"      Visible vessel DU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/26/416\" title=\"picture 2C\">",
"      Visible vessel GU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/24/10628\" title=\"picture 3\">",
"      Gastric ulcer with adherent clot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/48/17167\" title=\"picture 4A\">",
"      Ulcer with clean base Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/62/41966\" title=\"picture 4B\">",
"      Ulcers with low rebleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/4/13383\" title=\"picture 5\">",
"      Epi MPEC hemostasis NBVV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31986\" title=\"picture 6\">",
"      Duodenal vessel after Rx Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2573|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?39/39/40574\" title=\"movie 1\">",
"      Bleeding duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/7/22651\" title=\"table 1\">",
"      Acute Rx severe UGI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/10/22699\" title=\"table 2\">",
"      Predictors repeat ulcer bleed",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/11/27838?source=related_link\" title=\"calculator 1\">",
"      Calculator: Rockall score for upper gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/56/19329?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blatchford score for gastrointestinal bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15528?source=related_link\">",
"      Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=related_link\">",
"      Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=related_link\">",
"      Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=related_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23514?source=related_link\">",
"      Treatment of active variceal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_15_24827="Short stature v delay of growth";
var content_f24_15_24827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential features of familial short stature and constitutional delay of growth and puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Feature",
"      </td>",
"      <td class=\"subtitle1\">",
"       Familial short stature",
"      </td>",
"      <td class=\"subtitle1\">",
"       Constitutional delay",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parents' stature",
"      </td>",
"      <td>",
"       Small (one or both)",
"      </td>",
"      <td>",
"       Average",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parents' puberty",
"      </td>",
"      <td>",
"       Usual timing",
"      </td>",
"      <td>",
"       Delayed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birth length",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Growth (0 to 2 years)",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Normal to slow",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Growth (puberty)",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bone age",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Delayed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Timing of puberty",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Delayed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Puberty growth rate",
"      </td>",
"      <td>",
"       Lower range of normal",
"      </td>",
"      <td>",
"       Diminished",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adult height",
"      </td>",
"      <td>",
"       Short",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24827=[""].join("\n");
var outline_f24_15_24827=null;
var title_f24_15_24828="Morphologic abnormalities MDS";
var content_f24_15_24828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Morphologic abnormalities in myelodysplastic syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Lineage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Peripheral blood",
"      </td>",
"      <td class=\"subtitle1\">",
"       Bone marrow",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Erythroid",
"      </td>",
"      <td>",
"       Ovalomacrocytes",
"      </td>",
"      <td>",
"       Megaloblastoid erythropoiesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Elliptocytes",
"      </td>",
"      <td>",
"       Nuclear budding",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acanthocytes",
"      </td>",
"      <td>",
"       Ringed sideroblasts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stomatocytes",
"      </td>",
"      <td>",
"       Internuclear bridging",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Teardrops",
"      </td>",
"      <td>",
"       Karyorrhexis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nucleated erythrocytes",
"      </td>",
"      <td>",
"       Nuclear fragments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Basophilic stippling",
"      </td>",
"      <td>",
"       Cytoplasmic vacuolization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Howell-Jolly bodies",
"      </td>",
"      <td>",
"       Multinucleation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Myeloid",
"      </td>",
"      <td>",
"       Pseudo-Pelger Huet anomaly",
"      </td>",
"      <td>",
"       Defective granulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Auer rods",
"      </td>",
"      <td>",
"       Maturation arrest at myeolocyte stage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypo-granulation",
"      </td>",
"      <td>",
"       Increase in monocytoid forms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nuclear sticks",
"      </td>",
"      <td>",
"       Abnormal localization of immature precursors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypersegmentation",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ringed shaped nuclei",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Megakaryocyte",
"      </td>",
"      <td>",
"       Giant platelets",
"      </td>",
"      <td>",
"       Micromagakaryocytes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypogranular or agranular platelets",
"      </td>",
"      <td>",
"       Large mononuclear forms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Hypogranulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multiple small nuclei",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: List AF, Doll DC. The Myelodysplastic Syndromes. Wintrobe's Clinical Hematology, 10th edition, Lee GR (Ed), Lippincott Williams &amp; Wilkins, Baltimore 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24828=[""].join("\n");
var outline_f24_15_24828=null;
var title_f24_15_24829="Commisural calcium in MS";
var content_f24_15_24829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Commissural calcium predicts outcome after mitral valvuloplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients undergoing valvuloplasty for mitral stenosis, the presence or absence of commissural calcium on an echocardigram was predictive of survival with freedom from death, mitral valve replacement, or repeat valvuloplasty (p",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cannan CR, Nishimura R, Reeder GS, et al. J Am Coll Cardiol 1997; 29:175.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24829=[""].join("\n");
var outline_f24_15_24829=null;
var title_f24_15_24830="Incision for sigmoid colostomy";
var content_f24_15_24830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incision for sigmoid colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 172px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACsAOQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKgiu7ea6ntopke4gCmWMHLJuyVyO2cGgCeiiigAooooAKKKKACiuUlni17xw2nmIS2eholxKzKCv2t8+WoyM7kjy3B/5ar7V1dABRRRQAUUUUAFFFZ8OoG71GW3s13R2z7LiYgFQ2M+WOc7hlDnBGDjr0ANCiiigAooooAKKKKACiiigAooooAKKKKACiiigArE0zVGufFet6aS2LOK2kAJGP3gfkcA/wdyenatuuX0mNU+I3iNlGDJp9gzdefnuR/SgDivj3r2s6ZdeGLDRbu8to76WU3BtV+YhTGEDMMMq7nwSCDyOtdp8Lw58A6NLK7yNcQm53u2S3mMXBz9Grzr9oC+js/F3gszHI8q8kQc43o9q4J+YDGFbrke1eqeCbf7J4N0G3K7fJsII8emI1HagDaooooAKxfGeup4a8L6jq7xGZraPMUI6zSsQscY92dlX8a2q4zxxItz4o8FaRIpMdxqD3j+4t4Xdf/IhiP8AwGgDU8D6C3h7QI7e5kE+pTu11f3A/wCW9y/Mj/TPAHZQo7Vv0UUAFFFFABUN5dQWVrLc3c0cFvEpd5JGCqoHcmsjxd4hh8P6c0pa3NyVLRxTO6BgMbjlUY8Z9OTxx1ryW88UXGq6tZXerxXd5DBLmO2tlKI8+3dFCig/61iB1ZsLuYsqhloA7vWvEupam1noehKbHWdSLSiRwGewsQcG5dCMB2xhEb+JhkfI4HX6Nplto+l21hZKwggXau9izMepZieSxJJJ7kk1keBdFu9M06e81swSa/qUv2m/kiHyhuiRKepSNcIM9cE9WNdJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcpp6lfinrrHGH0bTwORk4nvM/wDoQrq64m8nXTviZe3snKvo9tEF9zdSKP1cUAeYftKRzzeMPDS27qP9BukZG2kkOUAwG6nIB49DX0HGixxqiABVAAA7AV4L8Z4ftfxo8IWbBik9qFPJA/14AyB169PrXvlABRRRQAVxOuRx3Xxd8JLn95aaZqNz9AXtox/6Efyrtq8x1LUWh/aK0e22sY30CWEt2V5JTIo+pFq//fNAHp1FFFABWdretafotpJcajdQwhUZ1R5VRpMdlDEZOcD6kUniW21C88P6hbaNeR2WoywMkFy67hE5HDY9v8g9K+edT1rw74ZujJHq1mdRlGx00kM1zcMxA2fbZvMuJcnoYwgH95e4BqeINZGs6zNJqdteSXUNqZz9rAto7WFcnzmg8wmJRk/PI53Z+WN+laHw28G61GkN/qD3MWraijtbTNBhNJtTjeY1IAS4myvBGQFGQNpQwfDi2n8Ta5NY6rp9lovh7Qr7yRp8L+Z/aOqBfMLzybmMjRAAldzZcZLNtGPeIBIsEYnZHmCgOyLtUtjkgZOBntk0AJbxCCCOFWdljUIC7lmIAxkk8k+5qSiigAopsjrHGzyMqIoLMzHAAHUk1x1zq8HivUBpVi7DSUQXNzdlcJcRqwwkZ7oxHL/dIDBSTkqAdnRXHeAJpNVhv/Fd1LMsOqkNaRSORHFZxlhEwU8AuCZCf9sDtWnovi7Q9d1GWz0W/TUHiUs8tqjSQLggYMwHl7ufu7s9eOKAN6iiigAooooAKKKKACiiigAooooAK848ViRviMkQb5JdNtfl9xfx8/8Aj1ej15t46byfiHorvystrGir6n+0bPn8Nw/OgDlfiMjy/tDeF8D5IdPgbd/dLXy+3cKwr3OvFPEyrN+0/oMRDkHSoSdvT5WvHGfbKr+OK9roAKKKKACvKr/T9Q1bWvG2taGyy6vpV/aRaejHAkNvAJHiJ7B/tU8ee24ntXqtcX8IT9o8FR6owAk1e6udSYgAZEszsn5JsH4UAdJ4e1e11/Q7HVdPYta3kSypuGGUEfdYdmByCOxBFaFcf4ZgOi+Ndf0iMY0+7VNWtkA4jd2ZZ1HoC6rJ9ZWrsKAPOfi5o6X9gkRGqSNcvndbahPD5G0AZCRhsggnORgdT6jw+90PQPC1nc3tlp0UrRq1w+0eaX24CqZMvw7lFyGcMWwdpr1z4k6gL7UZYnuoDp8SEIQyFSR/rNzdsEdC6MNvAbpXn2uzQ2nibwD4RuZN+parrMGragpATbBESIIXQcENgtggH5RkZoA9V+FHhsaVbJDM/mNpINsT2lu5AJbqc8dS77B/dCEDhq9GqvaWVrZtcNaW8ULXEpmmMaBfMkIALNjqcAc+1WKACio7meK1gknuZY4YI1LPJIwVVA6kk8AVw/jbxckNp5Gl3EMkVwhQXVrK7yo/YIFQoT6ZkWgC1448SpYRm2tpblZkbEoSHarDbnHmOpXHIJ2K7Adh1Hmc9jrXiKGHRNLSxk1LUsXd7M28xafYSDB8xyd7zTqCo+Yts3AFFOaWDTdQ1jUba1Vb2TWnZSY76QytaxA7hLdYOI1PBWBizvgDcq7sezeGNAtfD9i8Nu0k9xPIZ7q7mwZbqY/ekcjAzwAAMAAAAAACgDFj+H+l3YgfxLJNr00ShVjuzttUA6BbZcRADtlS3AyTXXQxRwQpFBGkcSAKiIMKoHQADoKfRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnXxC8hPHfhWS6nmiTyJVURLuLP9t08qOo4JHPtnr0PotedfEhQfGvg5pM+RukVuuM/aLQqPzX9KAOakhe4/avR1UsttoSOx7KCZFz+b47dTXtVeQ+H7YyftPeKrocrDoVvE3sXdSP0SvXqACiiigBshxGxwTweBXJfB9VT4UeDhHjH9kWp49TEpP65rr64P4RY0rSL7wlMX+2eH7l4BvGDJbOzPbyD2KHb/vIw7UAdimnWy6rJqQVzdyQrAWMjEBFJIAXOByTkgZOBnOBTNZ1S00ixe6v7q3tox8qtPIEVnI4UEkcn0q5LIsUTyPkIiljgE8D2FeR+KPEt54p1aKx8OTXUNjCplnunhlht4UC5Lzu3lshHICqTu6njJABzjqLiafVvF0iWmk2UZ1DU0CyJtXOViJLeZuZiu1GOMfdznFfP19e67rfjH/hN7i6jj1i6vVubQQ3UDSW6R4wzxE5CKoUDdjdjv1rrPHviCbXoLLQvDq3cfh61ma4fVGtpkXUrsKm642xqdkYBBVQcgMD12is+xmt7p7PUNW1OOW5ghVDBqWrQLMzqqbJAs9qyGLCjCE8+p/iAPo7Tvite2fhvTb3xf4avNIubhUkaSbCW7xtnDiT5ljbgHypWQjOMnqdW++Idpe2EVzomo2EEYcl3luLOdZFHUKRdKAe+cn6V4L4H0e/8U3tpqep6ZaNpk1w8djZ2sMNrLq0q8SbmhUL9lXkySYOcBQGLYP0T4d+Huj2ZuL3WtP0zUtavGD3Fy1kgRcAKscSkHZGqgADOTjJJJJoA4Obxe+qym1bxj5jykgW+jbb24+gjtozs47tKwHGa2dC8Kaxdt/okV/ods4/e6rql39t1edT1WPJZLYEEjIJI/uKeR6laWsFnAsNpBFBCv3Y4kCqPoBUtAGdoGiad4f01LHR7VLa2BLkDJZ2PV3Y5Lse7MST3NaNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc/4u8TReH4LeKG2k1DWL1zFY6dCcPcP3JPRI1HLOeFHqSAQCx4n8QWvh6xSa4SW4uZn8m1s4BumupSCQiD14JJOAACSQATXzJ8V/Hk2jfEfw/cazq8r6lbmQ31lbHdZ6cCyPFEpAzI6sg8x8Hd0AGAg7/4h+Kf+EBt/tN/dQat8Qb+MopVSI7KF1YlbdSDhQUHH33O0t/CB5NoPw41PXvD3inxz4tEjeVbzz2kRJUy3RYsZD6qpJ6YBJOPu8gHf6PNF4z+ImueJvDuqtYNqVytroWqROdjzW0K+Zb3EZHKSAl1UjOIyRg4z6p4R8cS3N5/Y3iyz/snXUcRDPEF02MjyyScE4JCk84O0ttYj528KWV58NrlENpcap4ZuhFc3cEbEOpXaRNHhgVkVhgMMcow9Cv0FZ2umeP8Aw/FI13b6vBKHe21JLdCNgKnyZ0PfJwUwPuZ+VgCAD0GivMLPUfEPg3UBZX0M2q6dJnyrfzt8wH/TvJIQZfUwyHzAPuNKBiu/0LWdP17T1vdJukubcsUJXIKMOqspwVYdCrAEdxQBoVzHirwsdUv7TWNHvTpfiKzQxw3ipvSSInLQzR5HmRk84yCp5Ug5z09cJ4815Zp7nQ7a/On21vB9p1rU0fb9htuTsVu00gBA7quW67MgHkHjrxT4lGj6xqfiCys72x0ydrVL221gQ2s03G6KGFoN8hBBU5JwQwDHaxHmF54nk1022jeI/EdpaeDx+9ubHw6xR5nIz8z3G0O2QMksygrwvAr1jxz8P/G3jS3sLjTNI0GHwnbQKmm+Hr2eeCSFBwsreXtAkZf4S3yhsEZ3GvKNf+FOt2Tkah8O/EMeTkyaVfpeKcE8hdjtznoWz/UAw9JnsIr872msIRbpFGLSyE7SgAfJIYJkOMAEufmYnOBxjs/BWh6n4pkil1C91O58LPKbfTtJju7mIatMAcxosrv5cSYPmyZOFBAyenPeE/AcWr63H59lqCaXDOLR7S9tViu7q7DBvskQ3Fh8uN0jYEali2OBX2L4D8IReH7Zbm8S2fV3iETG3j2QWkXUW9uv8MQP4ufmbnAABZ8JeGv7IaS+1GWO61q4jSKWWNNkUEaj5YIE/wCWcS9h1J5Yk9OkoooAKKKKACiiigAooooAKKKKACiiigAooqtfX9tY/Z/tcyxm4mWCIHJLyNnCgD2BPsASeAaALNR3E0Vtbyz3EqRQRKXkkkYKqKBkkk8AAd6yYtXmvfEDWWmwpJZ2hIvrp87Q5BxFH/eYHBY9FGByTx5pJrHjHxX4t1nS7aCGysWt3szZXkKyx2sLPtNzcD+OWQK3lwA7dp3MQCN4BuD4r6dr2pSaP8PoJPEGrbCxmCtFZW4zjfLMRyuc42Bi2CB7S3ltc+D7J7yHzPEHjbVWWLzniPzAHJVUB/dQICTgHGSCxLEk6mn2Wj+AtMa2tW86+uA00stzKoln2D5pJGAAWNFwOAFQYVRyFMqajcfZrO6j00Ta7fwCON1h2bIwR+8kV2BWNWkyUyWI7Z4AB57pvg64u9UfSr27e81SSONvEWreaxS3XcXjtrbOCsjB8Fxgqhzwzpix4y1iC18L+MpdItLMW2n3NnoCW9zD+6KL5YKKP4QPtB2nplR2rstL0MW81ppFs0sllBIdR1C7lGWvLhnJALdD84LH0CovTgcPe6RHqXw0+JEhEtxJPq13JOe7RwTA4QdAyomB/tAHmgDqNPuINF8fmxu0KW1zG02nXURDJKs0m54pRjKlZSSjdCJNuc9eN8VeHbnwH4z1PxX4J1WJWndZNT0OeUQRTFwRGQdpUZYHn5TncNxztrQ8YW8WrfCjw/r1lLHFd2sUXk6ggdikLfLkhRlkI2llOPUHcBXZ20d3rnhqw1OMwt4gs42ido2AjuCPlkTP/POTG5T2+Ru2CAXtE13SvGGkrFLasY7uJ2a0u4wdyK2xsjkYzjg89MgVxuraVYWE0usaHrd9Y3cdy1tPqgXzVtwgAWG9jYgyxjJAdvnQMp3hfmqhoV/H4D1y1v5S7+DdbRUbUGi8v7Dcg7VW4RfljycqXCqAwAIXBJ9G1rSZBqUOqaZGjTsVgvYDgLd25OCGzxuTJZSe25ejcAHMXHjfW1b/AIRybRWtfGk6EW2zM1k8edrXYk4xGmQxRtr5KqAcg1neAdIsfEHlGynlu/DGl3jzfaZQCda1EMfMunP8UaP93HBdePljTPifxY8dahpvibxZpNnq9hby6vdyafdyNBmextIljSNEffjY4dyVC5BLnqSRQ8KfHPxP4X0W20bTZ/C11p2m26wwmeGSN5AF4+64yx6E469e5oA+0q8++JHjGWxc6LobyjUZCkc9zDGJGt9+dkcSk4e4cAlEPCgGR8IPm8b039obxJrhhtYbPSrFrqXyVngt7m7lC7fvxxgAOckKASBuIDYHNel+CfDuo+E5Dq+saDPfTtvaN4LkXNzaq+DI0ikDzJ3IzI8ZOcKqjaiigDp/h34QXQbZL3UIwdXki8sAyeaLSEnd5KOeWJb5nkPMjkseNoXs6o22r2FzZ2t1FdR+RclREz/IWLdFwcEHjGDznjrV6gAooooAKKKKACiiigAooooAKKKKACiiigDI8VahLp2ju1pt+3XDrbWobkedIdqk+wzuPsprl5Z7g2t7rUWbm5sv+JRpTz/NukLrE8zY4y0uAcAfKnbcaXWNbMvxJs7JZkm0+w0mfVWRVVh5quYgd3XIBcY+vemgx23g7wQhSaRHkgmZIl3NKyW8k/TPJLR/iSKAK/xC0m/sfBmi+HvDgv44bnUbeG+vbWRklgtg5lnnMg5DNtOT3Ln1rE8O3vn3UlxawRyxXU81/Z2k2V3hpCft1038KAABdwydgCj5dx6r4nX+r2Oj6Bq+jreLHbarayX9tFGWkktXJjkUoMkkF1bAz92vOk03VfF/i3UfBlk72HhvTPLj12eMeXNqErR/dBIyIQFCKo42jH3cUAbFtrGn3cereIdR1IXHhrTJleW8YKW1mZULrHGM/LCjFdiDO9uSSMlr154k1mDR1vrq2Sy8W+IpvsOj6dIPmtoN5wzj+8FJkc9OFHasLT9RsvFi6l4g1e3jtfh34XmkexiSIqt35IGJAAfnAK5HY5C8/NW34DE2o6jq3xB8WKI7aJpF0hJfne2tyMMVAzy3C4GSSD1DAUAdre31v4Q8PpbxRpItlZNJlpFjUlQANxJzl3IGeeSe/XlfDNiX+CNx5Ls01zHdXjvKDlnaV5GJ79fXmsP4zXzz+EtXvLY26efqCWxa4w261tN0kjKvfEiyfkKvQi+034J6ZbNsmneYpcFyxyDM7MFwe5AUc45/CgDqvA2njU/hNpen3saW4u9NEUqQAbU3qQQvGMDPHGK5b4BzXFl/wkGiXtyk7QXPnQspyrpgIWT/AGSFRuehciu7+HjB/AXh11ztbT4GGSScGMeteX/2pHoPxCk16BFmjuXltnS2B2NE7lxIAcnO6JlI6iVXB4kXAB3+vaLZXF3faJqAk/sfxFG6sqNtCXAGWC4HBdQWwcgmNsj5jngIPEPiTQY4/hn4fkTUPFcUrJFfyRsYrHTiAUuJc8FlDbFTPVRnjAbqPjD4jjj0aw0XQo21DxRrDq+jx27A+W6EMLlmwQI04JJ4YZHQkjyL4j+KNT0kN8PvCN2b/wAUXrFta1mGNUmnldv9TGAclvmCnB+RRjgK20An8L+OLPR/iJp/gT4eeH7XXbEXQj1XV7ld9xdS7szT7+AQo3fMcg9BxjPs+o319q2vT6B4QaLT4bXH9qaukKsYGIBWCFSNrTEYJLAhFIyCWAHCeB/BMPgCxt/DHhryT431WES6lqSgN/Z1tuAZhn0+6gI+d13MMKQN2bwv4j8AzNceBbm51LR5JPNn0i+l85jI7Zdo3I3gtncSXIBJJBzwAN8CWugeGfH01qda1PWdX1pZhaXWpBpJYlgKia380n++N+0KvAHX5SfVJpooEDTSLGpZUBY4G5iAB9SSB+NeP2lhban4y8L63rb3Xh7WZtYvLnTNPmh3STIbVI5UbGQmREWJPXPHJFeieP3RPB+plsb9gEXOP3pYCP8AHftoAoeOtGDwy6taQebIsXlX0C9bq2GSQP8ApomS8Z9QRkBiRs+FL24vtBtZbzDXAXY8ijCzY6SL6qwwwx/ex2qLSvEFvfTXEM+yCVbue1jRnz5vlfeYcccdqk8I2Fzpfhuwsb2RZJrePy8qcgKCQq5wM4XAz7UAa9FFFABRRRQAUUUUAFFFFABRRRQAU0OpdkDAsoBK55Gen8jTq5+Ivb+PblWT91e6dG0bZ/ihkcOPymT9aAOd8KeHn/4Si41EmHbarc6XNCc7tjTvMp9OVkiP4mtHSbu6sPA7xR2ou9T0MG3aAjc7+VwGA67niww9d4+ldZHbwxTTTRxqss2DIwHLYGBn8OKxNaMujak2tQQGazeIR38cSbpdq5KSqBy23LAjqVPGSoBANjT7221GxgvbGZJ7WdBJFKhyrqRkEV4pf6N410dPFVnr/ib/AIplLYyWup30kYSeNnY/ZpiSHRiX2GRSMrjG0gAet6Fp0FpPdXWl3Svpl9i4SBADGsjZLSIw7PkEjpnJHU5t61pVjrmlXOm6taxXdhcpslhlGVYf55B6gjIoA8E1nUP+Er0jwjpHiTSLjS/C0BEt5Dp2n3EkFyyrsito9iZCr87t/CAq7WJ5HbT6/eeMLqw07w/pGt6XYQtuWe9017eNmHCuAwACxj5wDgs4iAGA+PPvEv7PGpaFePqXwv16e2IDN/Z15Mygk9Qsq4PTgBh25avF/GviPx74c1D+z9e06XStRJIE/m3AecdPlcylXUHuvegD6U+OOiC00Lw4mnzywW2l70MfltIZY2j2Hb2ZxjJB5KGRsHFXvGV1HJ8MtC1W3nSawj1CK7e76iKNmfbNkdlZ0JODxk+4+S9J+LHjuwzEfE9xcxEgvBqf+loxB6HzQ2OR2x07V6T4N+O0ccKaT42sIE0CJpxJb6YoAkEkbL5JjLYMPzuQAeuwfw8gH0Z8Jbi8Xw//AGZqW0TWQQRKg+VYSNoQHvtdJEz6KK878aXckWumylt5LfVtUvClrYQP5bNMejgnOEO0FpEG0hQxCSxgNm+DviZ4V8OWEUmh62de8pJLa309IZEvrhHcyRIVZcPIjsy5BwyuTjIwe80Lw14lm0rU/FmoCybx9e20g06Ofd5GmxsAUgAwOR1Y4yWz2zkA8q8T63c/DHTprKBo9S+JGuMv9pXFkCw0+F3ASCEKuUzuG0Y6ndz8gOt4M0NPhXpcN+dHS8+I3iSZlsNIEzOlmrknDOxJUBRl3JJO3bngtR8Lvhxc+A9Sm8U/EIrqviy8lK6bYQS+bJJKcs8hJwC5ySWJ2ooLEjti6r8QvAmq+PNeuPEmsyLHb5SwvIIXlLT8gOhT/lnCo2p2cySufvCgDu9R8G21vpEPi/w5ca7L4rtnBvprYb55Jif3nm25Pz7cgeUGA2Abc4XN21+KHidIh/aHhQwQrbgz6ldrNYWdtIM5dzcIrbDlTtAJByAXyDXKeB9Hmu9JuNa8DN4u1We4uFtXF7fPpls8JQlZQzbnkRMBQVO/nt1Hpth4Stte0vSdO+ID6fqur6XIbtrOCeWSBQxYJvSRi0gABw0mckH3oAg8H6PZ+J9R8LeModevNWtNPsJoLX7RavB5s8hxJcjeAwDKCoXBUDGD66XjTVM6pZ20UD3C2com8lTj7TdbSYYAfb/WueiBFY8E1vay2qHy7HRII7feo3X0u0xwL0wsYOWfA4BAUZBJONp47/hHIrnWbnSrB2miAMd7dsSfIhfDSRAnO64mbl24wmOmEyAVNS06WC8gstTmj8owM91Mr/KLfcJ7uYgdPNl2RBTztDHNdz4Ns57Pw/D9siMN1cSTXk0ROTG80jSlD/u79v4Vz9hpQ1bxFfDzBNYQ3Sm7kx8krRf6m2jHTy487n9ZCR/eA7ugAooooAKKKKACiiigAooooAKKKKACsbxJp091HbXunEDU7BzNbgttWXIIaJzg4VgcZxwQrdq2aKAM3QtYttZtWlt98c0TeXcW8o2y28gHKOOx569CCCCQQTpVj6toiXV19vsJjY6sqeWt0i7g69QsidHX2PIydpUnNa0e4Rr5hUvgbiowM+1AGAdLu9FnnudBUTWsrGSTTCQi7ycs8TdFJySVPysecqSSb+ka3Y6ozx20227jH761lGyaH/eQ8j69D2JFaVQXFsk291/dXJjaNbhFUyRg+hIPcA4IIyBkGgCequpadY6patbanZ215bN96K4iWRD9QwIrJ2+JrDTbWON9M1m8VmWaWYtZBl/hOFWQbvXgA9sdK6CgDy7XvgL8PNXLN/YQsJj0ksJnhx9FB2f+O1wGp/spaFNKzaf4k1SBc5AuIo5jn3I25r6D1bTLfVIEiumuVCNuVre5kgcHGPvIwPfpmqOneHIbC8jni1DV5RHnEVxfyyocjHIYnP40AeNeB/2fLjwNrMeraPrmk6hexcxDU9JdgjcfMpWcYI5xwev0I9RS28eudsmq+GIhj766ZO5H4GcfzrpWswYrpBcXK/aMncJOY8jHyZ+76/WqEnh2zl0uOwmn1J4kk8zf/aE6ys3PWRXDEc/dzjpxwKAPNvFHw3vtVe7uPGnxFnjs7tPs8i2trDZYhJyYVkYuVRsAsufmwN2cACt4O8B/Dnw88cvhfwxeeIrxT8t48JmQn+8JZdsP4oc16Xpfg3w7pk/n2mkWv2nOftEq+dKD/vvlv1roKAOeWLxFqcDrdyWujROMYtG+0TqCOzsoRW/4C49+9M87Q/CEItIAzXtyxkEEeZru8fHLHqznjBZjgDqQBVmTS9Tubmc3mtyLaPuCQ2cAhKqTxlyWYnHdSv0FULW50HQJprXRLV7zUZiWljtczzSMDjMsrHjBPWRhigDa1ixuNRgjhhv57GItmYwACV1x91X/AIPcgZ9CDzWBb4uYhonhFEs9Kh3Jc6hF/Cc/MkJ/jlJzukOQp67myBc/szUdcj/4qFltbJxg6baylt4I6Sy4BYeqqAvYlhXQQQxW8EcNvGkUMahEjRQqqoGAAB0AoAi06yt9OsYLOzj8u3gQIi5JwB6k8k+55PerFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUbRL6ymtpJJ4kkGC8ErROvurKQQasUUAMgj8qGOMu8mxQu9zlmx3PvT6KKACiiigAooooAKKKKACqOrxajNCiaVdW1rIW+eSeAzYXH8IDLznHJyPar1FAHPReGElkEus6jqGqSD+CaXy4fp5UYVGH+8GPvW3aWtvZW6QWcEVvAn3Y4kCKPoBxU1FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutting disc of skin for colostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24830=[""].join("\n");
var outline_f24_15_24830=null;
var title_f24_15_24831="Passing endotracheal tube";
var content_f24_15_24831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Technique for passing the endotracheal tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endotracheal tube is rotated 90 degrees counterclockwise (B) as it is passed through the cords, changing the initial horizontal (widest) axis of the bevel (A) to the vertical (narrowest) axis (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murphy MP, Barker TD, Schneider RE. Endotracheal intubation. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_15_24831=[""].join("\n");
var outline_f24_15_24831=null;
